Functional annotation of orphan human P450 enzymes: heterologous expression and substrate searches by metabolomic approaches by Xiao, Yi

    
FUNCTIONAL ANNOTATION OF ORPHAN HUMAN P450 ENZYMES: 
HETEROLOGOUS EXPRESSION AND  
SUBSTRATE SEARCHES BY METABOLOMIC APPROACHES 
 
By 
Yi Xiao 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in 
Biochemistry 
December 2014 
Nashville, Tennessee 
 
Approved by: 
 
Professor F. Peter Guengerich 
Professor Richard Armstrong 
Professor Alan Brash  
Professor David Hachey 
Professor Kevin Schey 
  
ii 
 
 
 
 
 
 
 
 
 
To my dearest Mom and Dad, and my beloved wife Wenyue, for their 
unconditional love and support 
 
 
 
 
 
 
 
 
 
 
  
iii 
ACKNOWLEDGEMENTS 
 
I would like to express my sincere thanks to my mentor and Ph.D. advisor, 
Dr. F. Peter Guengerich, for his enormous guidance and support, and for 
securing the research funding (National Institutes of Health Grants R37 
CA090426 and P30 ES000267). He is not only a role model as a great scientist 
but also committed to mentoring and teaching students. He was always there to 
encourage and lead me through the twists and turns of scientific journey and also 
gave me the time and freedom to explore, learn, and grow. He is also very 
supportive for my overall professional development. Working with him is a great 
privilege and I am forever indebted to him.  
I would also like to thank the members of my thesis committee, Dr. 
Richard Armstrong, Dr. Alan Brash, Dr. David Hachey, and Dr. Kevin Schey, for 
their guidance on my thesis projects and advice on my career development. The 
project would not have proceeded so well without their support. Dr. David 
Hachey helped tremendously on state-of-the-art MS instrumentations and data 
interpretation. Dr. Alan Brash gave invaluable help on characterizing fatty acid 
analogs by liquid chromatography. Dr. Richard Armstrong and Dr. Kevin Schey 
always offered valuable input and thoughtful suggestions. I was so fortunate to 
have the privilege of meeting with the amazing panel of experts every six 
months. 
The laboratory is a very supportive community. Kathy Trisler, Ellen 
Rochelle, Dr. Martha Martin, Lindsay Folkmann, and Leslie Nagy made 
  
iv 
everything run smoothly. Dr. Wade Calcutt, Dr. Raku Shinkyo, Dr. Goutam 
Chowdhury, and Dr. Qian Cheng are great sources of advice, training, and 
friendship. I also owe thanks to all the brilliant and kind people that I have worked 
with on my thesis projects for their generous assistance on instrumentations and 
data analysis. I am thankful for my friends I met in the Interdisciplinary Graduate 
Program and the community of international students/scholars. They provided 
me with support, empathy, and fun, which greatly expanded my life in Nashville 
and prevented me from tunnel vision. I am eternally thankful to them and wish 
them the best in their future endeavors. I am also thankful for Vanderbilt 
International Scholar Program for providing full stipend support for two years and 
the director, Dr. Kathy Gould, for her support and guidance.   
Last but certainly not least, I would like to thank my Mom and Dad for their 
enduring love and support and Wenyue, my beloved wife, for her companionship 
through this journey. 
  
v 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS ..................................................................................... iii	  
 
TABLE OF CONTENTS ......................................................................................... v	  
 
LIST OF TABLES ................................................................................................ viii	  
 
LIST OF FIGURES .............................................................................................. viii	  
 
LIST OF ABBREVIATIONS ................................................................................... xi	  
 
CHAPTER I ........................................................................................................... 1	  
INTRODUCTION ................................................................................................... 1	  
 
Cytochrome P450 enzymes .............................................................................. 1	  
Human cytochrome P450 enzymes .................................................................. 4	  
Increasing need for functional annotation of gene products ............................ 10	  
Functional annotation of gene products and applications  
in studying human P450 enzymes .................................................................. 12	  
Targeted strategies ...................................................................................... 12	  
Untargeted strategies ................................................................................... 16	  
Heterologous expression systems for human P450 enzymes ........................ 34	  
E. coli expression systems ........................................................................... 34	  
Baculovirus expression systems .................................................................. 36	  
Yeast expression systems ........................................................................... 38	  
Mammalian cell expression systems ........................................................... 40	  
Orphan human P450 enzymes covered in this thesis work ............................ 40	  
P450 2W1 .................................................................................................... 40	  
P450 2S1 ..................................................................................................... 41	  
P450 2U1 ..................................................................................................... 41	  
P450 4V2 ..................................................................................................... 42	  
P450 4X1 ..................................................................................................... 42	  
P450 4Z1 ..................................................................................................... 42	  
CHAPTER II ........................................................................................................ 44	  
HUMAN CYTOCHROME P450 2S1 IS REDUCED BY  
NADPH-P450 REDUCTASE ............................................................................... 44 
 
Introduction ...................................................................................................... 44	  
Materials and methods .................................................................................... 45	  
Chemical and reagents ................................................................................ 45	  
Anaerobic reduction ..................................................................................... 45	  
  
vi 
Enzyme activity determination of human P450 2S1 towards AQ4N ............ 46	  
Determination of NADPH consumption rates ............................................... 46	  
Results and discussion .................................................................................... 47	  
CHAPTER III ....................................................................................................... 51	  
FUNCTIONAL ANNOTATION OF ORPHAN HUMAN  
P450 2W1, 2S1, AND 4X1 BY METABOLOMIC APPROACHES ...................... 51	  
 
Introduction ...................................................................................................... 51	  
Experimental procedures ................................................................................ 53	  
Materials and reagents ................................................................................ 53	  
Tissue extracts ............................................................................................. 53	  
Enzymatic incubations ................................................................................. 54	  
LC-MS based metabolomics and data analysis ........................................... 55	  
Characterization of oxidation products by human P450 2W1 ...................... 56	  
Kinetic analysis of P450 2W1-mediated oxidations ..................................... 57	  
Purification of sn-1 and sn-2 LPC ................................................................ 58	  
Chiral analysis .............................................................................................. 59	  
Other methods ............................................................................................. 60	  
Results ............................................................................................................ 60	  
New approach for doublet searches ............................................................ 60	  
Searches for P450 2W1 substrates in malignant  
human colorectal cancer extracts ................................................................ 62	  
Searches for human P450 2S1 substrates in human lung extracts ............. 65	  
Searches for human P450 4X1 substrates in bovine brain extracts,  
human liver extracts, and human lung extracts ........................................... 65	  
Specificity of 18:1 LPC as a substrate for other human P450 enzymes ...... 67	  
Characterization of oxidation products ......................................................... 68	  
Steady-state kinetic analysis of P450 2W1 reactions .................................. 68	  
Isomer specificity of lysophospholipid oxidation .......................................... 72	  
Substrate specificity for other phospholipids ................................................ 75	  
Chiral analysis .............................................................................................. 76	  
Discussion ....................................................................................................... 77	  
CHAPTER IV ....................................................................................................... 81	  
HETEROLOGOUS EXPRESSION OF HUMAN P450 ENZYMES ..................... 81	  
 
Introduction ...................................................................................................... 81	  
Experimental procedures ................................................................................ 82	  
Materials and reagents ................................................................................ 82	  
Heterologous expressions in E. coli cells ..................................................... 82	  
Heterologous expressions in insect cells ..................................................... 83	  
Other methods ............................................................................................. 83	  
Results ............................................................................................................ 84	  
Previous expression trials of P450 4Z1 in E. coli expression systems ........ 84	  
  
vii 
Expression trials of P450 4Z1 with new N-terminal modifications ............... 85	  
Troubleshooting P450 4Z1 expression in E. coli expression systems ......... 86	  
Expression of P450 4Z1 and 4V2 in insect cells .......................................... 88	  
Expression of human P450 2U1 in an E. coli expression system .............. 102	  
Expression of human 46A1 in an E. coli expression system ..................... 102	  
Discussion ..................................................................................................... 103	  
CHAPTER V ...................................................................................................... 108 
SUMMARY AND CONCLUSIONS .................................................................... 108	  
 
PUBLICATIONS ................................................................................................ 115	  
 
REFERENCES .................................................................................................. 116	  
 
 
 
  
viii 
LIST OF TABLES 
 
Table 1. Classification of human P450 enzymes based on their  
substrate specificities. ........................................................................................... 8	  
Table 2. NADPH oxidation rates. ........................................................................ 48	  
Table 3. Comparison of doublet search approaches. ......................................... 62	  
Table 4. Doublets identified by Matlab program and confirmed 
 in Qual Browser.................................................................................................. 64	  
Table 5. EI GC-MS analysis of TMS derivatives of the oxidation products 
 of fatty acids and LPCs by human P450 2W1. .................................................. 69	  
Table 6. Steady-state kinetics of P450 2W1-catalyzed oxidations ..................... 72	  
Table 7. Previously tested N-terminal modification for 4Z1 expression. ............. 84	  
Table 8. New N-terminal modifications for heterologous expression 
 of P450 4Z1 in E. coli. ........................................................................................ 85	  
Table 9. Expression levels of P450 4V2 and 4Z1 in insect cells. ...................... 102	  
Table 10. Doublet searches with LTQ and LTQ-Orbitrap instruments. ............. 112	  
  
ix 
LIST OF FIGURES 
 
Figure 1. Common reactions based on the high-valent iron chemistry  
catalyzed by P450 enzymes. ................................................................................ 3	  
Figure 2. Routes of elimination of the top 200 most prescribed drugs in 2002. .... 7	  
Figure 3. The topology of crystallized P450 2C5/3LVdH. ..................................... 9	  
Figure 4. Classical and 21st century approaches in functional annotation of  
gene products. .................................................................................................... 11	  
Figure 5. Identification of P450-mediated procarcinogen activation and  
DNA damage with umu assay. ............................................................................ 15	  
Figure 6. Untargeted LC-MS based strategies for functional annotation of  
orphan enzymes. ................................................................................................ 18	  
Figure 7. A strategy to identify monooxygenation reactions using 18O2 gas. ...... 24	  
Figure 8. Advantages and disadvantages of different analytical methodologies  
for metabolomic studies. ..................................................................................... 27	  
Figure 9. LC-MS data visualized in heat map by spectrolyzer ............................ 28	  
Figure 10. LC-MS data visualized in three dimensions. ...................................... 29	  
Figure 11. LC-MS data visualized in matrices: before (A) and after (B)  
data deconvolution. ............................................................................................. 31	  
Figure 12. DoGEX is used in the analysis of substrates of P450 7A1 with  
human liver extracts. ........................................................................................... 33	  
Figure 13. Flowchart for heterologous protein expression in insect cells with  
Bac-to-Bac system. ............................................................................................. 39	  
  
x 
Figure 14. Reduction kinetics of P450 2S1 (with AQ4N). ................................... 49	  
Figure 15. LC-MS/MS analysis of the m/z 538/540 doublet. ............................... 66	  
Figure 16. Specificity of 18:1 LPC as a substrate for human P450 enzymes. .... 67	  
Figure 17. EI GC-MS fragmentation patterns of TMS-derivatized oxidized  
fatty acid moieties. .............................................................................................. 71	  
Figure 18. Baseline separation of sn-1 and sn-2 isomer of 18:1 LPC. ............... 73	  
Figure 19. Isomer specificity of lysophospholipid oxidation. ............................... 74	  
Figure 20. Rates of P450 2W1-catalyzed oxidation with  
different 18:1 lysophospholipids. ......................................................................... 75	  
Figure 21. Chiral analysis of P450 2W1-catalyzed epoxidation of  
FFA C18:1 and 18:1 LPC. ................................................................................... 76	  
Figure 22. P450 spectrum of expressed human P450 4Z1 from E. coli cells. .... 86	  
Figure 23. Quantitative immunoblotting to detect P450 4Z1 expression. ........... 87	  
Figure 24. Sequence information of P450 4V2 in pFastbac. .............................. 89	  
Figure 25. Sequence information of P450 4Z1 in pFastbac. ............................... 90	  
Figure 26. P450 spectra with P450 4V2 and 4Z1 from insect cells. ................... 91	  
Figure 27. Sequence information of NADPH-P450 reductase in pFastbac-dual. 93	  
Figure 28. Sequence information of 4V2-RhPV-IRES-OR in pFastbac. ............. 95	  
Figure 29. Sequence information of 4V2-lg10-OR in pFastbac. ......................... 97	  
Figure 30. Sequence information of 4Z1-RhPV-IRES-OR in pFastbac. ............. 99	  
Figure 31. Sequence information of 4Z1-lg10-OR in pFastbac. ....................... 101	  
Figure 32. Doublet searches enhanced by HRMS ............................................ 111	  
  
xi 
LIST OF ABBREVIATIONS 
 
APCI   atmospheric pressure chemical ionization 
AQ4 1,4-bis{[2-(dimethylamino)ethyl]amino}-5,8-dihydroxy-
anthracene-9,10-dione 
AQ4M 1-{[2-(dimethylamino-N-oxide)ethyl]amino}-4-{[2-
(dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-
dione 
AQ4N 1,4-bis{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-
dihydroxyanthracene-9,10-dione 
BSTFA  N,O-bis-(trimethylsilyl)-trifluoroacetamide 
DLPC   L-α-dilauoryl-sn-glycero-3-phosphocholine 
ESI   electrospray ionization 
GC-MS   gas chromatography–mass spectrometry 
HPLC   high-performance liquid chromatography 
IPTG   isopropyl-β-D-thiogalactoside 
IRES   internal ribosome entry site 
HRMS  high resolution mass spectrometry 
LC-MS  liquid chromatography–mass spectrometry 
LPA   lysophosphatidic acid 
LPC   lysophosphatidylcholine 
LPE   lysophosphatidylethanolamine 
LPG   lysophosphatidylglycerol 
  
xii 
LPI   lysophosphatidylinositol 
LPS   lysophosphatidylserine 
MOI   multiplicities of infection 
MS   mass spectrometry 
NMR   nuclear magnetic resonance 
P450   cytochrome P450 
PC   phosphatidylcholine 
pFBB   pentafluorobenzyl bromide 
PPARα  peroxisome proliferator-activated receptor alpha  
TMCS   trimethylchlorosilane 
TMS   trimethylsilyl 
TMSI   trimethylsilylimidazole 
UPLC   ultra-performance liquid chromatography 
RhPV   Rhopalosiphum padi virus 
 
 
  
1 
CHAPTER I 
 
INTRODUCTION 
 
Cytochrome P450 enzymes 
Cytochrome P450 (P450) enzymes are versatile biocatalysts with broad 
substrate specificities. The heme protoporphyrin IX prosthetic group, linked with 
the axial cysteine residue, gives P450 enzymes their unique chemistry and 
spectroscopic properties. Research on P450 enzymes can be traced back as 
early as in 1964, when Omura and Sato named the enzyme “cytochrome P450” 
for “pigment 450” due to the maximal absorbance at 450 nm following reduction 
and CO binding (1, 2). Absorbance at 450 nm of the Fe2+·CO complex has been 
used to determine the concentration of the active enzyme (3, 4).   
It is now well accepted that P450 enzymes are a superfamily of proteins 
with similar molecular weight (~ 50 kiloDaltons). To date, more than 20,000 P450 
genes have been identified across all kingdoms of life with sequence information 
stored in the P450 database (http://drnelson.uthsc.edu/CytochromeP450.html). 
With the launching of genome sequencing projects towards numerous other 
organisms, sequence information for more and more P450 genes will become 
available.  
In order to give a unique name for each P450 enzyme, a nomenclature 
system was adopted: P450 enzymes with > 40% amino acid sequence identity 
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are categorized in the same family and are designated with a number (P450 1, 
P450 2, etc.); subfamilies with > 55% amino acid sequence identity are 
designated with a letter following the number (P450 1A, P450 1B, etc.); each 
enzyme in the subfamily is named with another number (P450 1A1, P450 1A2, 
etc.). 
P450 enzymes are versatile biocatalysts. With numerous members found 
in nature, P450 enzymes are well known for their involvement in diverse and 
important physiological functions. Substrates for P450 enzymes include a 
plethora of compounds involved in both primary and secondary metabolism (e.g., 
hormones, cholesterol, fatty acids, terpenoids, antibiotics, pesticides, herbicides, 
environmental toxins). In addition, P450 enzymes can catalyze a variety of types 
of reactions.  
The most commonly seen reactions are monooxygenation reactions, with 
stoichiometry shown below (RH is a substrate and ROH is the monooxygenated 
product): 
RH + O2 + NADPH + H+  →  ROH + H2O + NADP+ 
Some P450 enzymes also catalyze reduction (5), carbon-carbon cleavage 
(6), dealkylation (7), ring expansion (8), desaturation (9), and other reactions 
based on the same high-valent iron chemistry (Figure 1) (10).  
To appreciate their physiological significance and utilize their catalytic 
activities for our benefit, studies on P450 enzymes have been continuing in many 
industries for decades, including drug discovery, insect control, and crop science. 
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Figure 1. Common reactions based on the high-valent iron chemistry 
catalyzed by P450 enzymes.  
From (11).  
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Human cytochrome P450 enzymes 
Human P450 enzymes are membrane-bound proteins either targeted to 
endoplasmic reticulum or to mitochondria. Redox partners and lipids are needed 
to mimic membrane environment so that catalytic activities of P450 enzymes can 
be reproduced in vitro for functional assays (12): microsomal P450 enzymes can 
be reconstituted with NADPH-P450 reductase (12-14); mitochondrial P450 
enzymes can be reconstituted with adrenodoxin reductase and adrenodoxin (15).  
It is well established that human P450 enzymes play crucial roles in many 
important biological processes. Initial interest in the field was fostered in 
endocrinology (16), chemical carcinogenesis (17), and drug metabolism (18). 
Substrates for human P450 enzymes include a variety of compounds, including 
cholesterol, vitamins, steroids, fatty acids, eicosanoids, environmental toxicants, 
and drugs (19, 20).  
Studies on human P450 enzymes have been continuing for decades and 
knowledge on their catalytic properties has been expanding. To date, it is well 
accepted that human P450 enzymes are involved in the metabolism of ~ 75% of 
drugs currently on the market (21-23) (Figure 2). The majority (99%) of human 
P450 enzyme-mediated drug metabolism is carried out by only a few enzymes 
(i.e., human P450 3A4, 3A5, 2C9, 2C19, 2D6, 1A1, 1A2, 2B6, and 2E1) (23). 
Although current knowledge suggests that only < 1% of drug metabolism is 
contributed by other human P450 enzymes, it is increasingly appreciated that 
those less-studied P450 enzymes can play important roles as well. For example, 
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human P450 2J2 metabolizes pomalidomide, terfenadine, and ebastine (24, 25), 
and recombinant human P450 2J2 has been made commercially available for 
pharmaceutical companies to study P450 2J2-mediated drug metabolism. 
Another good example is the activation of several duocarmycin analogues by 
human P450 2W1 (26). Human P450 2W1 and 2S1 are also involved in the 
metabolism of several fluorinated 2-aryl-benzothiazole antitumor molecules (27). 
These less-studied human P450 enzymes have also been found to be involved in 
vitamin metabolism (28), tumor prognosis (29-31), and a recessive degenerative 
eye disease (32). Thus, the need to investigate all human P450 enzymes is 
warranted. 
Human Genome Project identified 57 human P450 enzymes, which have 
been classified by their substrate specificities (Table 1). It has to be noted that 
one P450 enzyme can have substrates that fit into two different categories. For 
example, human P450 27A1 oxidizes both cholesterol (an endogenous steroid) 
(33) and vitamin D3 (34); human P450 2W1, 2S1, and 2J2 are all involved in drug 
(xenobiotics) metabolism (24, 26, 27); human P450 1A2, 2C8, and 2C9 also 
oxidize fatty acids (35).  
Among the 57 human P450 enzymes, 13 of them are considered ‘orphans’ 
because knowledge towards their physiological significances is limited. Much 
effort has been devoted to functionally annotate these orphan human P450 
enzymes in recent years. For example, heterologous expression systems of a 
few orphan human P450 enzymes have been established (36-42); expression 
profiles of most orphan human P450 enzymes have been characterized (41, 43-
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51); a few catalytic activities have been reported (5, 20, 28, 36, 39-42). The 
investigation of catalytic activities of orphan human P450 2S1, 2W1, and 4X1 is 
the focus of Chapter II and III. 
Functional studies of human P450 enzymes have been greatly benefited 
from the development of heterologous protein expression systems (i.e., 
Escherichia coli, baculovirus, yeast, and mammalian cell expression systems). 
Historically human P450 enzymes were isolated from human tissue samples 
(52). One major disadvantage of this method is the basal expression of other 
P450 enzymes in the same tissue and the technical difficulties in enzyme 
purification without cross-contamination from these enzymes. Other problems 
include the difficulties in obtaining human tissue samples and in purifying 
enzymes without losing much catalytic activity. Thanks to the development of 
heterologous protein expression systems, now it is a common practice to express 
recombinant P450 enzymes in many laboratories.  
The first P450 enzyme (P450cam) was crystallized in 1985 and the 
structure was solved two years afterwards (53, 54). The crystal structure of the 
first mammalian microsomal P450 enzyme was solved in 2000 (55) (Figure 3). 
Since then, the number of Protein Data Bank deposits of human P450 enzymes 
has been increasing, but none of them was generated with orphan human P450 
enzymes, partially because of the difficulties in expressing P450 enzymes in 
good yield. Although tools have being developed for decades to facilitate 
heterologous protein expression, it can still be the bottleneck for research 
projects, especially if large amounts of protein are needed. Heterologous 
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expression of several human P450 enzymes for functional studies is the focus of 
Chapter IV. 
 
 
 
 
 
 
Figure 2. Routes of elimination of the top 200 most prescribed drugs in 
2002.  
Human P450-mediated metabolism represents the listed clearance mechanism 
for 73% of the top 200 drugs. For the P450 (CYP)-mediated clearance 
mechanisms, the majority (46%) are carried out by members of the CYP3A 
family; followed by 28% by members of the CYP2C family; 12% for CYP2D6; 9% 
for members of the CYP1A family; and 2% for both CYP2B6 and CYP2E1. From 
(22).  
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Sterols Xenobiotics Fatty Acids Eicosanoids Vitamins Unknown 
1B1 1A1 2J2 4F2 2R1 2A7 
7A1 1A2 4A11 4F3 24A1 2S1 
7B1 2A6 4B1 4F8 26A1 2U1 
8B1 2A13 4F12 5A1 26B1 2W1 
11A1 2B6  8A1 26C1 3A43 
11B1 2C8   27B1 4A22 
11B2 2C9    4F11 
17A1 2C18    4F22 
19A1 2C19    4V2 
21A2 2D6    4X1 
27A1 2E1    4Z1 
39A1 2F1    20A1 
46A1 3A4    27C1 
51A1 3A5     
 3A7     
 
 
Table 1. Classification of human P450 enzymes based on their substrate 
specificities.  
From (20). 
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Figure 3. The topology of crystallized P450 2C5/3LVdH.  
From (55). 
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Increasing need for functional annotation of gene products 
The classical biochemistry paradigm of the 20th century involves several 
events that happen in a chronological order: 1) identification of an in vivo 
phenomena of physiological significance; 2) development of in vitro assays to 
purify the key proteins involved; 3) information about the protein (or an antibody) 
can be used to clone a cDNA, and its nucleotide sequence can be determined; 4) 
the gene product is finally annotated with physiological significance (Figure 4) 
(56).  
Due to the advent of genome sequencing technologies, today we have 
sequence information of all the genes in numerous organisms including humans. 
Open reading frames and splicing variants can be predicted and confirmed easily 
by experiments. However, methods for rapidly annotating gene products with 
physiological significances are still being developed, and functional annotation of 
gene products is considered one of the grand challenges in modern biomedical 
research. Even in an organism as well studied as E. coli, functions of only 54% of 
the gene products have been experimentally determined (57). Not surprisingly, 
the prevalence of gene products with unknown function is well beyond 50% in 
higher plants and animals (58). Therefore, strategies are urgently needed for 
functional annotation of gene products in a backward order: from individual 
coding sequences to their physiological significances in vivo (Figure 4) without 
any preconceived biological phenomena.  
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Strategies for functional annotation of gene products often include the 
followings: sequence comparison with other genes (in DNA levels and in protein 
levels); characterization of expression profiles (information at different 
developmental stages may help); the establishment of heterologous protein 
expression and purification methods; reproducing physiological significances with 
functional assays in vitro and in vivo. Although the establishment of heterologous 
expression methods can still be very problematic (see Chapter IV), the more 
daunting challenge is choosing the ‘right’ functional assays to investigate 
possible protein functions (see Chapter III). Among the numerous functional 
assays that can be chosen from, some are as easy as an in vitro incubation that 
takes only a few hours, some are as daunting and time consuming as developing 
genetically modified animal models followed by further experiments. 
 
 
 
Figure 4. Classical and 21st century approaches in functional annotation of 
gene products. 
From (56). 
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Functional annotation of gene products and applications in studying 
human P450 enzymes 
Targeted strategies 
Sequence similarities 
In some cases, insight into protein function can be hypothesized from 
sequence similarities. Given the fact that human P450 3A4 and 3A5 share 85% 
amino acid identity, it is not surprising that their substrate specificities overlap 
(59). Another example is human P450 7A1, whose catalytic activity was deduced 
from its animal orthologue (rat P450 7A1) (60).  
The advantage of this approach is its potential to annotate gene function 
in the most quick and efficient manner. However, the major problem is that 
proteins with high sequence similarities can still have completely different 
functions. For example, although human P450 2C8, 2C9, 2C18, and 2C19 share 
sequence similarities between 77% and 93%, their substrate specificities differ 
tremendously (61). Enzymes in the enolase and vicinal oxygen chelate (VOC) 
families (62) also catalyze a variety of enzymatic reactions. 
 
Structure insight and in silico docking 
Another appealing approach is protein crystallization and computational 
modeling. However, protein-substrate interaction is a dynamic process and 
structure obtained by crystallization can only provide information of a snapshot. 
Since it is well accepted that P450 enzymes usually undergo major 
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conformational changes upon ligand binding (63), predicting substrate 
specificities from protein crystallization and in silico docking can be very difficult. 
In addition, P450 enzymes can have large active sites, which requires 
tremendous computational power to predict potential substrates. For some P450 
enzymes, it can also be very challenging to obtain large amounts of purified 
protein (40). Thus, successful example of functional annotation of P450 enzymes 
by this approach is limited. 
 
Trial and error by functional assays 
Potential function of a protein can be hypothesized and tested with 
functional assays. Commonly used rationales include expression profiles, 
regulatory mechanisms, and analysis of phenotypes observed from 
animals/patients without the functional protein.  
This strategy can also annotate protein function in a very quick and 
efficient manner. Successful examples include the identification of fatty acids as 
substrates for many orphan P450 enzymes, although with low catalytic 
efficiencies (36, 39, 40, 42, 64). However, there could be endless hypothesized 
functions waiting to be tested, and it could be even more laborious if an individual 
method has to be developed for each hypothesis. In terms of fatty acid oxidations 
by orphan human P450 enzymes, although there are scenarios where fatty acid 
oxygenation products do have biological activities (65), it is not clear that any of 
these fatty acid oxidations catalyzed by orphan human P450 enzymes are 
physiologically important. It is hard to believe that fatty acid oxidation is the only 
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physiological significance for these orphan human P450 enzymes (39, 40, 42), 
and it is very likely that there are other substrates waiting to be identified. 
 
Screen with compound libraries 
Compound libraries can be used to enable high-throughput capability. 
A library of procarcinogens can be incubated with P450 enzymes to 
screen for P450-mediated procarcinogen activation and DNA damage (Umu 
assay) (Figure 5) (36, 64, 66, 67). Several substrates of human P450 2W1 have 
been identified with this approach, with low turnover rates (36).  
Another method is to test a few representatives from each chemical class 
of potential substrates (e.g., fatty acids, steroid hormones, cholesterol, vitamins). 
Substrates of each class can be mixed together and used as a substrate pool for 
enzymatic incubations. Reaction products can be analyzed by a liquid 
chromatography-mass spectrometry (LC-MS) method that detects every 
compound in the substrate pool. If any catalytic activity can be detected towards 
one of these compounds (e.g., cholesterol), then the pool (of cholesterol) can be 
expanded with more cholesterol analogs to find the ones with better catalytic 
efficiencies. However this approach has not been successful to date.  
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Figure 5. Identification of P450-mediated procarcinogen activation and DNA 
damage with umu assay.  
Chemicals are incubated with Salmonella typhimurium cells (containing the 
plasmid pSK1002) and a metabolic system. The metabolic system can be either 
liver microsomes or a recombinant cytochrome P450 system expressed within 
the cells. The formation of DNA adducts would block the replication of the 
modified strand and generate regions of single-stranded DNA, which would 
activate the binding of protease LexA followed by the activation of more than 30 
other genes. umuC, one of the activated gene, encodes a translesion 
polymerase that the bacteria use to bypass DNA adducts and replicate. A 
reporter plasmid (pSK1002) contains the regulatory region of the umu gene 
followed by the coding sequence of LacZ. Thus, the generation of DNA adducts 
in Salmonella typhimurium cells would activate the expression of β-galactosidase 
and the production of β-galactosidase, which can be quantified using a 
colorimetric assay. From (67). 
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Untargeted strategies 
Untargeted approaches have the potential to identify substrate(s) in a less 
biased way. The general hypothesis is that substrate(s) of a P450 enzyme can 
be identified in the tissue/organ where the enzyme is expressed. This is a 
common hypothesis seen in many metabolomic studies (68-71). Caution must be 
taken in that this hypothesis may not work if the enzyme of interest works only on 
xenobiotics. 
 
Binding assays 
One approach is to look for ligands that bind to the protein of interest. 
Ligand-bound protein can be immune-precipitated or immobilized so that the 
ligand can be enriched and characterized afterwards. This approach is commonly 
used in laboratories that investigate signal transduction pathways and protein-
protein interactions (72). One successful example in identifying small molecule 
ligands is the discovery of linoleic acid as an endogenous ligand of the 
hepatocyte nuclear factor (HNF) 4α (73). Another good example is the 
identification of interaction between unsaturated fatty acids and the nuclear 
receptor Nur77 (74). 
The major disadvantage of this approach is that ligands could disassociate 
from the targeted protein during protein purification. Thus, only ligands with very 
high affinities can be captured. Another disadvantage of this approach is the fact 
that the binding of a ligand to a protein does not necessarily warrant any 
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physiological significance. Thus, this approach has not been used widely for 
functional annotation of P450 enzymes. 
 
Metabolomic approaches for functional annotation of orphan enzymes 
The metabolome represents a chemically diverse mixture of 
physiologically relevant compounds, including those that have not been reported 
in literature or not commercially available. Recent technological advances in 
global metabolomic profiling enabled simultaneous screening of thousands of 
metabolites from a variety of chemical classes, making them useful tools for 
functional annotation of orphan enzymes (68-71, 75).  
Metabolomic studies can be conducted both in vivo and in vitro, and 
require state-of-the-art analytical instruments to analyze complicated biological 
matrices (if working with genetically modified model organisms or human 
samples) or incubation mixture (if working with cell lines, subcellular fractions, 
and reconstituted enzymes) in order to pinpoint any interesting features that 
could shed light on enzymatic activities. Commonly used instruments include LC-
MS, gas chromatography–mass spectrometry (GC-MS), and nuclear magnetic 
resonance (NMR). Further characterization of these identified features also 
require the use of sophisticated methodologies, such as high resolution mass 
spectrometry (HRMS), preparative HPLC, and NMR. LC-MS based metabolomic 
approaches that can be used for functional annotation of orphan enzymes are 
summarized in Figure 6. 
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Figure 6. Untargeted LC-MS based strategies for functional annotation of 
orphan enzymes.  
One strategy utilizes genetically modified model organisms, with the orthologue 
of the protein knocked-out or over-expressed. The metabolome from body fluids 
(or tissues) can be analyzed by LC-MS. As an alternative, tissue extracts can be 
incubated with and without the protein or the co-factor. A 18O2 labeling strategy 
can also be used (Figure 7) to identify monooxygenation reactions. Specialized 
software systems can be used to identify doublets or features that are consumed 
(putative substrates) or generated (putative products) in a time- and enzyme-
dependent manner. From (56). 
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Study design 
Based on the hypothesis that the substrate(s) of the enzyme can be 
identified in the tissue/organ where the enzyme is expressed, the metabolome 
from the tissue/organ or from cultured cells with a modified enzyme expression 
level can be compared with that from control samples with an unchanged 
enzyme expression level. Alternatively, tissue extracts can be incubated with and 
without enzyme or co-factor and be scrutinized for any differences. Many 
specialized software systems can be used to identify difference(s) between sets 
of data (76-81). This approach has the potential to identify different classes of 
reactions (e.g., reduction, dealkylation, ring expansion). 
Although tissue samples from humans are not always easy to obtain, 
genetically modified model organisms can be used as an alternative. Thanks to 
the development of modern molecular biology techniques, it is now a common 
practice to knock out or over-express a gene in many model organisms (e.g., 
mouse, zebrafish, fruit fly). Any phenotype resulting from the modified gene 
expression level could shed light on the physiological function of the gene. The 
phenotype could be as dramatic as embryonic lethality (which may require 
tissue-specific genetic modification for further investigation), or as subtle as tiny 
changes in the abundance of only a few chemicals. Characterization of such 
subtle changes often require the help of state-of-the-art analytical instruments 
and require careful study design to exclude false positives and reduce variances. 
Successful examples include the studies of fatty acid amide hydrolase (FAAH) 
(71), organic anion transporter (Oat1) (70), and mammalian 
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glycerophosphodiesterase (GDE) (69): the metabolome from knockout mice was 
compared with that from wild-type mice. Chemicals that accumulate in the 
knockout mice were later confirmed as substrates.  
Besides the technical requirement in generating genetically modified 
model organisms and the time spent in producing them, one major problem with 
studying genetically modified model organism is that the orthologue may not 
always have the same function as the gene in humans, or there could be no 
orthologue in the model organism at all. Another concern is the possibility that 
other proteins may show compensatory activities in the model organism (there 
are 103 mouse P450 genes and 89 rat P450 genes, in contrast with 57 P450 
genes in humans). Thus any phenotype due to the functional loss/gain of the 
gene could be masked.  
Cultured mammalian cell lines can also be modified to increase or 
decrease the expression level of a gene of interest, transiently or permanently. 
Controls would be cells transfected with a blank expression vector. For example, 
the integral membrane enzyme α/β-hydrolase domain–containing 3 (ABHD3) 
was transiently over-expressed in HEK293T cells and the accumulated 
phospholipids were confirmed to be the substrates (68).  One of the advantages 
of studying cultured cells is the lower cost compared with generating genetically 
modified model organisms. It is also much easier and takes less time to modify 
the expression level in cultured cells. A ‘rescue’ experiment can be used to 
provide solid evidence about physiological relevance, if the phenotype of the 
permanent knockout cells can be rescued by transient over-expression of the 
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gene. In addition, cell lines from many different human tissues are available for 
experiment. Therefore, issues with orthologues (i.e., no corresponding 
orthologue in model organisms, orthologues in model organisms have different 
functions) are no longer a concern. If the protein of interest is expressed in 
human liver, cell lines originally from human liver (i.e., HepG2) should be used 
due to their physiological relevance. Disadvantages of using cultured cells 
include low protein expression levels and compensatory effect. Also, the extent 
of substrate accumulation or product consumption in cultured cells may not be as 
much as it would be in genetically modified model organisms (depends on the 
level of protein expression and abundance of substrate in the system). Another 
disadvantage is that most phenotypes cannot be observed by naked eye and 
have to be characterized by complicated assays. 
Modified cell lines (protein of interest over-expressed or knocked out) can 
also be incubated with tissue extracts. The metabolome from modified cell lines 
can be compared with that from ordinary cell lines.  
Isolated recombinant enzymes (isolated membrane/microsomal fractions; 
purified enzymes) can also be incubated with tissue extracts for untargeted 
metabolomic studies (14, 64). Controls are incubations without the enzyme or 
without co-factor. This approach provides reduced level of complexity in 
background and less burden to analytical methodologies, so that the chance of 
identifying a subtle phenotypic change may increase. Compensatory effect is 
less of a concern, depends on the purity of the isolated protein. One 
disadvantage of using purified enzymes is the need to establish heterologous 
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protein expression systems. If a high protein expression level of a microsomal 
P450 enzyme cannot be achieved for protein purification, co-expression of the 
enzyme and NADPH-P450 reductase with a bi-cistronic expression vector could 
be used for functional assays (82): coding sequences of both the enzyme and its 
redox partner are connected with an internal ribosome entry site (IRES) so that 
both sequences will be transcribed on a single mRNA and translated individually; 
since both P450 enzyme and NADPH-P450 reductase are membrane-targeted 
proteins, isolated membrane fractions can be used to reproduce catalytic 
activities. If a high protein expression level of a mitochondrial P450 enzyme 
cannot be achieved for protein purification, co-expression of the enzyme, 
adrenodoxin, and adrenodoxin reductase can also be achieved with a tri-cistronic 
expression vector, in which the three coding sequences are connected with two 
IRES sequences (83). Since adrenodoxin is a soluble protein and is not 
membrane-targeted, functional studies have to be conducted with whole cells 
rather than with isolated membrane fractions (if expression is achieved with an E. 
coli expression system) (83). For tri-cistronic expressions in cells with 
mitochondria subcellular structure (i.e., mammalian cells, insect cells), isolated 
mitochondria supplemented with extra adrenodoxin can be used for functional 
assays (84). 
An approach was recently developed in Guengerich lab to identify 
monooxygenation reactions after incubations (85). This approach is based on the 
fact that most P450-mediated reactions involve the incorporation of an oxygen 
atom into the substrate, such that the product is 16 amu heavier. Thus, for 
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incubations performed with equal amount of 16O2 and 18O2 gas, the 
monooxygenated products would show up with M/M+2 doublet patterns in the 
mass spectra, which can be identified by a specialized computer software system 
(14, 64, 85). Technically, the mixture of the reconstituted P450 system and tissue 
extracts (corresponding to the localization of the P450 enzyme) are added into 
the bottom of Thunberg tube while NADPH is added into the neck (Figure 7). Air 
is removed by several cycles of vacuum and purging with argon. Then the 
samples (under vacuum) can be charged with either 16O2 gas or 18O2 gas, 
followed by tipping the tube to add NADPH into the incubation mixture to start the 
reaction (figure 7). Both incubation mixtures (one with 16O2 gas and another with 
18O2 gas) are combined before extraction, so that doublet patterns are expected 
for monooxygenated products. Controls are incubations with only 16O2 gas or 
without NADPH. This methodology identified a group of fatty acids as substrates 
of human P450 1A2, 2C8, 2C9, and 4F11 (14, 64). In principle, this approach can 
be used with sulfotransferases, epoxide hydrolases, and any other enzymes that 
catalyze reactions incorporating a co-factor that can be modified with a stable 
isotope.  
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Figure 7. A strategy to identify monooxygenation reactions using 18O2 gas.  
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Analytical methodologies for metabolomic studies 
The success of metabolomic studies very much depends on the 
sophisticated analytical instruments that are used to identify small changes in 
complex mixtures. One important contributing factor is sensitivity, as high 
sensitivity ensures the detection of chemicals at very low concentrations. NMR 
(86), LC-MS (14, 68-70, 85), and GC-MS (87) have all been used in metabolomic 
studies (Figure 8). Direct infusion coupled with mass spectrometry (MS) analysis 
is not commonly used due to the lack of chromatography separation. 
Ultra performance liquid chromatography (UPLC) coupled with MS 
analysis provides many benefits over NMR and GC-MS: accurate mass of the 
parent and fragment ions can be used to determine elemental composition; ultra-
resolving power of UPLC provides the capability to analyze complex tissue 
extracts; if needed, LC methods can be scaled up for metabolites isolation 
followed by NMR analysis. Low-molecular-weight compounds, particularly those 
relatively nonpolar ones that might be the substrates of P450 enzymes, can 
usually be resolved well with a reversed-phase octadecylsilane (C18)-based 
column and a water-to-acetonitrile gradient. Other columns are also available 
(e.g., HILIC columns can be used to resolve polar compounds (88)). 
Chromatography in metabolomic studies needs to be very reproducible. 
Achieving symmetrical peak shapes and baseline separations for all compounds 
in the metabolome are not feasible to accomplish, and are not crucial in most 
cases. In order to cover as many compounds as possible, multiple runs with 
  
26 
positive- and negative-ion electrospray ionization (ESI) and atmospheric-
pressure chemical ionization (APCI) are desired. Molecules bearing a positive 
charge (e.g., amines) ionize best with positive-ion ESI (with HCO₂H in mobile 
phase to help ionization); molecules bearing a negative charge (e.g., carboxylic 
acids) ionize best with negative-ion ESI (with NH4CH3CO2 in mobile phase to 
help ionization); neutral compounds (e.g., steroids) may ionize with APCI. 
Although there are other ionization modes available (e.g., APPI, MALDI), they 
are not commonly used in metabolomic studies.  
While compounds that ionize well in MS will be easily picked up during 
data collection and analysis, those that do not ionize well would be invisible. In 
order to cover as many compound classes as possible, a derivatization method 
with dansyl chloride has been developed to improve the sensitivity towards 
unactivated alcohols (89), which are common products of many P450 reactions. 
Dansylated compounds have excellent ionization properties in the positive-ion 
ESI mode due to the positive charge on the amine moiety (89). This method is 
particularly effective for uncharged molecules such as sterols and can improve 
sensitivities to up to several thousand fold (89). Dansylated compounds can be 
confirmed by MS-based fragmentation, which removes the dansyl group and 
produces characteristic daughter ions (89). Due to the increased hydrophobicity 
of dansylated compounds, tert-butyl methyl ether can be added to mobile phase 
to adjust retention time.  
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Figure 8. Advantages and disadvantages of different analytical 
methodologies for metabolomic studies.  
From  (90). 
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Data analysis software systems for metabolomic studies 
LC-MS data collected in full scan mode are stored in the format of a 
matrix: signal intensities are stored as entries; retention times and m/z values 
can be inferred from the i values and j values. For example, a LC-MS data file 
from a 90 second gradient scanning from m/z 200 to 400 can be stored in a 
matrix [a90,200]: 90 different i values represent 90 seconds; 200 different j values 
represent 200 different m/z values. The entry a60,100 represents the signal 
intensity of the ion with a retention time of 60 seconds and a m/z value of 300. 
LC-MS data can be visualized as a heat map with signal intensities 
represented with color (Figure 9). Alternatively, LC-MS data can be visualized in 
three dimensions, in which signal intensities are indicated with values in the z-
axis (Figure 10).      
 
 
 
 
Figure 9. LC-MS data visualized in heat map by spectrolyzer  
Data from Medicwave, Sweden.  
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Figure 10. LC-MS data visualized in three dimensions.  
From (56). 
 
The goal of metabolomic studies for functional annotation is to identify a 
few changes in abundance among thousands of chemical features in several 
sets of LC-MS data. A single LC-MS data file from a 30 min gradient collected in 
full scan profile mode could be as big as 900 Mb, thus it is not realistic for manual 
inspections. Data analysis software systems with solid mathematical foundations 
have to be applied to facilitate this process. A number of software systems can 
be used to analyze and compare sets of LC-MS data for metabolomic studies 
(e.g., enzymatic incubations with and without co-factor; samples from wild-type 
versus knockout model organisms), including MZmine (78, 79), MetAlign (80), 
MAVEN (81, 91), MetaboAnalyst (92), and XCMS (76), as well as those sold by 
mass spectrometry venders, such as MarkerLynx (Waters), Mass Profiler Pro 
(Agilent), and Metabolic Profiler (Bruker).  
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A common practice in data analysis with LC-MS data is to deconvolute 
(e.g., noise removal, peak detection) each data file before further analysis. 
Deconvolution keeps the highest intensity of the peak feature and removes 
unnecessary information (e.g., background noise and signal intensities on peak 
shoulders), thus makes it much easier for further analysis (Figure 11). To 
compare sets of LC-MS data, retention times have to be aligned across different 
data files. Principal Component Analysis (PCA) and Partial Least Squares (PLS) 
analysis are commonly used mathematical procedures for data comparison after 
retention time alignment (77). 
Signal normalization is another common practice used in data 
comparison.  Several methods can be used: 1) peak intensities can be 
normalized by the peak with the highest signal intensity, assuming the 
abundance of the coressponding chemical are constant cross all samples. A 
major concern is that the assumption above may not be valid. Another concern is 
that any error in sample prepration (lost of recovery) will significantly affect 
downstream data analysis and leads to increased false-positives; 2) peak 
intensities can be normalized by total ion intensities. This method is good only if 
small changes are occured across samples, thus total ion intensities are similar 
across all samples. Errors in sample prepration is no longer a major concern with 
this data normalization method.  
Although it is a common practice to normalize data before data 
comparison, it should be recognized that no data normalization is needed if 
sample preparation methods are highly reproducible and well designed.  
  
31 
 
 
 
Figure 11. LC-MS data visualized in matrices: before (A) and after (B) data 
deconvolution.  
Each entry in the matrices represents the signal intensity of the ion with the 
corresponding retention time (indicated by column number) and m/z value 
(indicated by row number). Data after deconvolution only have information of the 
highest intensity of each peak feature, and unnecessary information is removed 
(e.g., background noise and signal intensities on peak shoulders).  
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A software system, DoGEX (“Discovery of General Endo- and 
Xenobiotics”), was developed to identify doublet patterns after incubations with 
16O2/18O2 gas (85) (Figure 12). In principle, this software system can be used to 
identify any isotopic patterns in LC-MS data (85). 
All data analysis approaches inevitably bring many false-positives, which 
have to be excluded by manual inspections and appropriate control experiments. 
Parameters (e.g., signal intensity threshold) carelessly set-up could give 
tremendous amounts of false-positives and shall be carefully adjusted. Thus, it is 
always a good practice to optimize these parameters at the beginning of any 
metabolomic studies. Many P450-mediated fatty acid oxidation reactions (14) 
can be used to train software systems to pick up enzymatic activities with low 
turnover rates.  
 
Choice of instrumentation  
Instruments from Thermo, Waters, Agilent, and Bruker all can be used for 
metabolomic studies. Data files from different instruments all can be transformed 
and visualized as shown in Figure 9-11.  
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Figure 12. DoGEX is used in the analysis of substrates of P450 7A1 with 
human liver extracts.  
A reconstituted system with P450 7A1 was incubated with a human liver extract 
with 16O2/18O2 gas. LC-MS analysis of the product extract (derivatized with 
succinic anhydride) yielded the total ion current trace (A). Data analysis with 
DoGEX software generated the figure shown in B, where a green band indicates 
a potential doublet with M and M+2 intensity ratio near a targeted value, 0.95. 
The same region is expanded in C and shown in three dimensions in D, with a 
m/z 603/601 doublet identified. From (56).  
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Heterologous expression systems for human P450 enzymes 
E. coli expression systems 
Native human P450 coding sequences are typically expressed at low 
yields in E. coli expression systems. However, years of investigations have 
revealed several useful modifications and have made E. coli expression systems 
very popular for the expression of human P450 enzymes (33, 37, 64, 93-102). 
They are the cheapest and the least labor-intensive systems, and have the 
potential to produce active human P450 enzymes in large amounts. Thus, E. coli 
expression systems are usually tested for every p450 enzyme. The expression 
vector pCW(+ori), with two tac promoters arranged in tandem, has been tested 
for the expression of most human P450 enzymes (33, 37, 64, 93-102). 
Expression is normally induced by the addition of isopropyl-β-D-thiogalactoside 
(IPTG) to a bacterial culture with an OD600 between 0.5 and 1.3. Bi-cistronic and 
tri-cistronic expression systems can be established to co-express redox partners 
and P450 enzyme of interest, so that whole cell or membrane fractions can be 
directly used for functional assays (82, 83). DH5α has been the most used E. coli 
strain for heterologous expression of human P450 enzymes, but other strains 
have also been successful (e.g., JM109 (97), BL21 (64), TOPP3 (98), and 
TOP10 (103)). Trace elements (FeCl3, ZnCl2, CoCl2, Na2MoO4, CaCl2, CuCl2, 
H3BO3) (104), δ-aminolevulinic acid, and thiamine are also commonly added to 
the bacterial culture to improve P450 expression levels (33, 37, 64, 93-102). The 
coding sequence is usually constructed with a histidine tag to facilitate protein 
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purification with a Ni-NTA column (36, 64, 99). 
Besides expression temperature (23-30 °C) and expression time (20-48 
h), several contributing factors have been summarized in published review 
articles (93, 105), including codon-optimization, N-terminal modification, and 
chaperone co-expression. 
 
Codon-optimization  
As elongation proceeds, E. coli ribosomes may not readily recognize 
certain codon sequences commonly seen in coding sequences from eukaryotic 
cells. Expressions with optimized codon sequences that favor E. coli tRNA usage 
have the potential to tremendously increase protein expression levels (36, 99, 
106). Many public available tools can be used to design codon-optimized coding 
sequences, such as DNA 2.0 technology (106) and IDT (107). It is also believed 
that codons can be optimized to increase mRNA stabilities.  
 
N-terminal modification 
Mammalian P450 enzymes are membrane-bound proteins, and the 
subcellular location (mitochondria or endoplasmic reticulum) is largely 
determined by the hydrophobic amino acids at the N-terminal of the protein 
(108). Replacing these amino acids with coding sequences that are more friendly 
to E. coli expression systems has been commonly used to increase P450 
expression levels (64, 93-95, 97, 98, 100, 103, 109-112). Commonly seen N-
terminal modifications include amino acids MALLLAVFL (64, 93, 97, 109) 
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and MAKKTSS (113), although other modifications have been used as well (64, 
93-95, 97, 98, 100, 103, 109-112). These N-terminal modifications also favor the 
tRNA usage of E. coli and might increase protein expression levels with 
mechanisms similar to codon-optimization. 
 
Chaperone co-expression 
The ability of the host system to fold P450 enzymes and incorporate heme 
correctly also affects P450 expression levels. Chaperones aid in protein folding 
by providing a hydrophilic environment (114). Thus, co-transformation and 
subsequent induction of chaperones is frequently used to increase expression 
levels of P450 enzymes (36, 37, 99). Although other chaperone systems are also 
available for co-expression, GroES/EL is the most commonly used one to 
increase P450 expression levels. 
 
Baculovirus expression systems 
Baculovirus expression systems are known for their capabilities to express 
proteins with high molecular weights and with post-translational modifications. 
Formation of inclusion bodies is usually not a problem for baculovirus expression 
systems. The Bac-to-Bac system (Invitrogen, CA) has become more and more 
popular for baculovirus expression: native coding sequences can be integrated 
into the baculovirus genome by site-directed transposition, and the isolated 
genome can be transfected into insect cells to produce high-titer virus stock. Bulk 
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cultured insect cells (in suspension) can be infected with high-titer baculovirus at 
different multiplicities of infection (MOI) (ratio of competent virus to cells) to 
optimize protein expression yields (Figure 13). Supplemented with heme 
precursors (e.g., δ-aminolevulinic acid), baculovirus expression systems can also 
express mammalian P450 enzymes in large amounts (105) and are oftentimes 
the last resort to obtain functional protein, after failure in other expression 
systems.  
However, the disadvantages of baculovirus expression systems also 
made them the last approaches to be tested for protein expressions. One major 
problem is the high cost, both in time and consumables (i.e., expression medium, 
fetal bovine serum, T-flasks). A dedicated incubator (28 °C) is also required for 
culturing insect cells. If the expression vector needs to be constructed, and 
cryopreserved insect cells need to be revived, it often takes at least 1 month to 
be ready for the first expression trial even for highly experienced personnel. 
Accurately measuring the titer of the virus stock is another concern: plaque 
assay, which co-culture insect cells with diluted virus stocks in low melting point 
agarose, is the gold standard but takes 4-7 days to complete and is technically 
challenging (i.e., insect cells will be damaged if the agarose is too hot; agarose 
will solidify too soon if it is too cold); the qPCR based method usually 
overestimate the titer because it measures the amount of total genome DNA 
(virus with no infectivity will not be differentiated from fully-competent ones); 
immunoassays can give non-reproducible data (personal experience and 
communication with others). As a result, many highly experienced personnel 
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choose to perform expression trials with many different volumes of the virus 
stock, rather than spending time to measure the titer. To avoid the problems of 
setting up baculovirus expression systems from scratch, many institutes offer 
services to express proteins in insect cells for a charge. 
Similar to E. coli expression systems, bi-cistronic or tri-cistronic systems 
can be established in baculovirus expression systems to co-express P450 
enzymes and their redox partners (115-117).  
While codon-optimization helped increase protein expression levels in E. 
coli expression systems (36, 99, 106), it is still not clear if it can benefit 
baculovirus expression systems.  
 
Yeast expression systems 
Compared with E. coli, yeast has endoplasmic reticulum and in general 
gives less trouble with the formation of inclusion bodies. The disadvantages of 
yeast expression systems include low P450 expression levels and the 
requirement of special instruments to effectively break the cell wall. 
Nevertheless, yeast expression systems are still used in several laboratories for 
heterologous expression of recombinant P450 enzymes (40).  
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Figure 13. Flowchart for heterologous protein expression in insect cells 
with Bac-to-Bac system.  
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Mammalian cell expression systems 
Mammalian cells offer the closest physiological conditions to express 
mammalian proteins compared with all other heterologous protein expression 
systems. However, the basal expression of other P450 enzymes could be a 
problem. The high cost and low P450 expression levels also made mammalian 
cell expression systems less popular. 
 
Orphan human P450 enzymes covered in this thesis work 
P450 2W1 
Human P450 2W1 is preferentially expressed in colorectal cancer tissues 
(118, 119), and is regulated by gene methylation and reverse membrane 
orientation (119, 120). mRNA expression of human P450 2W1 has also been 
detected in colon, ileum, and testes in mice (121), but intensive searches in 
corresponding human tissues have not been reported. Increased levels of P450 
2W1 expression positively correlate with the degree of tumor malignancy, and 
with decreased 10-year survival in colon cancer patients (30, 122). 
Heterologous expression has been achieved in an E. coli expression 
system (36). Several P450 2W1-catalyzed reactions have been identified, 
including N-demethylation of benzphetamine (36), reduction of the drug 
candidate 1,4-bis{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-
dihydroxyanthracene-9,10-dione (AQ4N) (5), oxidation of indole and its 
derivatives (36, 119, 123), oxidation of the free fatty acid (FFA) arachidonic 
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acid (at a very low turnover rate) (36, 118), and activation of a variety of chemical 
carcinogens to genotoxic forms (36). 
 
P450 2S1 
The highest mRNA expression of human P450 2S1 has been detected in 
lung, followed by small intestine, spleen, and colon (47, 48, 124). Human P450 
2S1 protein has been detected in liver (46). P450 2S1 expression can be induced 
by 2,3,7,8-tetrachlorodibenzodioxin, indicating possible regulation by aryl 
hydrocarbon receptor (49, 125). 
Heterologous expression has been achieved in an E. coli expression 
system (36). The catalytic specificity of P450 2S1 has been controversial (56). 
Interestingly, a reduction reaction has been reported with AQ4N as the substrate 
(5).  
 
P450 2U1 
The strongest mRNA expression of human P450 2U1 has been detected 
in brain and thymus (39, 43). Moderate mRNA levels have also been detected in 
heart, kidney, liver, lung, testis, and leucocytes (39).  
Heterologous expression of human P450 2U1 has been achieved in a 
baculovirus expression system (39) and an E. coli expression system (37). 
Hydroxylations of fatty acids, both ω- and ω-1, have been reported (39). 
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P450 4V2 
Human P450 4V2 protein can be detected in retina and corneum (32, 51). 
Mutations in the CYP4V2 gene (chromosome 4q35.1) are associated with Bietti’s 
Crystalline Dystrophy (BCD), an autosomal recessive chorioretinal dystrophy 
featured with progressive night blindness (51).  
Human P450 4V2 has been expressed and purified from a baculovirus 
expression system and the ω-hydroxylations of medium-chain fatty acids have 
been reported (42). 
 
P450 4X1 
The highest mRNA expression level has been detected in trachea and 
aorta, followed by breast, ovary, uterus, liver, and kidney (50). Expression has 
also been detected in brain, especially in the cerebellum, amygdala, and basal 
ganglia (41). Expression of human P450 4X1 is regulated by the peroxisome 
proliferator-activated receptor (PPAR) α (50).  
Heterologous expression has been achieved in an E. coli expression 
system (41). Reported substrates include anandamide and arachidonic acid, both 
with very slow turnover rates (41). 
 
P450 4Z1 
High mRNA expression has been reported in breast, prostate, and ovarian 
tumors (31, 44, 126-128). Expression in normal breast tissue has also been 
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reported (50). Expression of human P450 4Z1 is also regulated by PPARα 
receptor (50). 
Heterologous expression has been achieved in a yeast expression system 
(40). The only reported reactions so far are fatty acid oxidations (40). 
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CHAPTER II 
 
HUMAN P450 2S1 IS REDUCED BY NADPH-P450 REDUCTASE 
 
Introduction 
Human P450 2S1 is one of the orphan human P450 enzymes with 
unknown physiological function (35, 56). Although human P450 2S1 has been 
expressed in E. coli, purified, and studied, its substrate specificity is still 
controversial (35, 36). To explain the limited catalytic activity of human P450 
2S1, Bui and Hankinson (129-131) attempted to measure the formation of 
Fe2+·CO complex under aerobic conditions and concluded that human P450 2S1 
is not capable of interacting with NADPH-P450 reductase or accepting electrons 
from it. In contrast, Nishida et al. (5) reported the observation of a Fe2+·CO 
complex anaerobically. In that study, human P450 2S1 was reported to reduce 
the pro-drug AQ4N to its mono N-oxide intermediate AQ4M [ 1-{[2-
(dimethylamino-N-oxide)ethyl]amino}-4-{[2-(dimethylamino)ethyl]amino}-5,8-
dihydroxyanthracene-9,10-dione] and finally to AQ4 [1,4-bis{[2-
(dimethylamino)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione]. A net 2-
electron transfer mechanism was proposed (5). In this study, we reproduced the 
anaerobic reduction of AQ4N, measured NADPH oxidation rates, and measured 
the reduction kinetics using a stopped-flow apparatus. Our results confirm that 
human P450 2S1 can efficiently accept electrons from NADPH- P450 reductase. 
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Materials and methods 
Chemical and reagents 
Deferoxamine, mitoxantrone, protocatechuate, and protocatechuate 
dioxygenase were purchased from Sigma-Aldrich (St. Louis, MO). AQ4N, AQ4M, 
and AQN were gifts from Dr. Klaus Pors (University of Bradford, UK). Human 
P450 2S1 (36) and rat NADPH-P450 reductase (132) were expressed in E. coli 
and purified as previously reported.  
 
Anaerobic reduction 
Anaerobic reduction experiments were performed using an OLIS RSM-
1000 stopped-flow instrument (On-Line Instrument Systems, Bogart, GA). 
Samples (in glass tonometers) were deaerated using an argon/vacuum manifold 
as described previously (133), utilizing a protocatechuate/protocatechuate 
dioxygenase oxygen-scrubbing system (134). Human P450 2S1 (2 µM) was pre-
incubated with NADPH-P450 reductase (4 µM), 160 µM L-α-dilauoryl-sn-glycero-
3-phosphocholine (DLPC), 100 mM potassium phosphate buffer (pH 7.4), and 
AQ4N (200 µM), and reduced upon the addition of NADPH (150 µM) from a 
second syringe. Rates were analyzed using the OLIS software and in GraphPad 
Prism (GraphPad, San Diego, CA). 
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Enzyme activity determination of human P450 2S1 towards AQ4N 
Reactions were carried out in duplicate in 1.5-ml Eppendorf tubes at 37 
°C. Anaerobic incubations were carried out under a nitrogen atmosphere inside 
of a glovebox (Labconco Protector® Controlled Atmosphere). Enzyme reaction 
mixtures typically contained 0.1 µM human P450 2S1, 0.2 µM NADPH-P450 
reductase, 160 µM DLPC, 1 mM desferoxamine, 100 mM potassium phosphate 
buffer (pH 7.4), and 200 µM AQ4N (5). After pre-incubation for 5 min, the 
reactions were started by the addition of an NADPH-generating system including 
100 µl of 100 mM glucose 6-phosphate, 50 µl of 10 mM NADP+, and 2 µl of a 1 
mg ml−1 solution of yeast glucose 6-phosphate dehydrogenase (3), and aliquots 
were terminated by the addition of three volumes of CH3OH (with 5 µM 
mitoxantrone as an internal standard) at times of 0, 1, 2, 3, 4, 5, and 6 min. 
Samples were prepared and analyzed by high-performance liquid 
chromatography (HPLC) as described (135) with a Thermo Hypersil GOLD 
column (150 mm × 2.1 mm I.D.) employing isocratic elution with 50 mM 
NH4HCO2 buffer (pH 3.6):CH3CN (89:11, v/v). Formation of AQ4M was used to 
determine enzyme activity.  
 
Determination of NADPH consumption rates 
NADPH oxidation rates were determined using 0.05 µM human P450 2S1, 
0.10 µM NADPH-P450 reductase, 160 µM DLPC, 1 mM desferoxamine, and 100 
mM potassium phosphate buffer (pH 7.4). For the determination of NADPH 
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consumption rates under anaerobic conditions, reconstituted enzyme mixtures 
were deaerated using an argon/vacuum manifold as described previously (133). 
Reconstituted enzymes were pre-incubated for 5 min at 37 °C in the presence or 
absence of AQ4N (200 µM). Reactions were initiated with the addition of NADPH 
to a final concentration of 150 µM and A340 was monitored (Cary 14/OLIS 
instrument). Rates were calculated using the value Δϵ340 = 6.22 mM-1 cm-1. 
Experiments were conducted in duplicate. 
 
Results and discussion 
The reduction of AQ4N to AQ4M is proposed to be a net 2-electron 
transfer mechanism (5). The hypoxic activation of AQ4N (to AQ4M) by human 
P450 2S1 was reproduced, measured to be 18 min-1 under anaerobic conditions 
and <0.5 min-1 under aerobic conditions.  
The steady-state rates of oxidation of NADPH by human P450 2S1 in the 
presence of NADPH-P450 reductase were also measured (Table 2). The higher 
oxidation rate under aerobic conditions confirms the acceptance of electrons by 
human P450 2S1 from NADPH-P450 reductase. Because the rate of AQ4N 
catalysis under aerobic conditions is very low, the increased NADPH 
consumption in the presence of AQ4N presumably comes from electron transfer 
to form partially reduced oxygen products instead of being transferred to AQ4N.  
The rate of product formation was measured to be 18 min−1. The 
anaerobic NADPH consumption rate without air in the presence of AQ4N was 28 
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min−1 and 13 min−1 in the absence of AQ4N, suggesting roughly quantitative 
coupling efficiency (i.e., all additional electrons are transferred to substrate 
AQ4N).  
The reduction step can be studied by monitoring the formation of the 
Fe2+·CO complex near 450 nm in the absence of O2, which will compete with CO 
and lead to P450 re-oxidation (136, 137). Our kinetic reduction data, measured in 
a stopped-flow apparatus (Figure 14), clearly showed a rapid increase in A450, 
indicating the acceptance of electron by P450 2S1 from NADPH-P450 reductase. 
 
 
 
  v (min-1) 
Plus air 
Minus AQ4N 23.3 ± 2.6 
 Plus AQ4N 45.7 ± 4.7 
Minus air 
Minus AQ4N 12.7 ± 2.9 
Plus AQ4N 28.2 ± 0.8 
 
Table 2. NADPH oxidation rates. 
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Figure 14. Reduction kinetics of P450 2S1 (with AQ4N).  
Stopped-flow absorbance trace of the reduction of P450 2S1 (2 µM) by NADPH-
P450 reductase (4 µM) in the presence of DLPC (120 µM) and AQ4N (200 µM) 
upon the addition of NADPH (150 µM). The rate was 40 s−1 (measured by 
averaging results from sixteen independent shots). 
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Bui and Hankinson reported that human P450 2S1 could not be reduced 
by NADPH-P450 reductase and that several catalytic activities of P450 2S1 
could be observed if reactions were supported by oxygen surrogates (i.e., 
hydroperoxides) (129-131). In contrast, Nishida et al. reported the observation of 
a Fe2+·CO complex produced by human P450 2S1 and AQ4N (rate not 
measured) (5). A serious caveat in the work of Bui and Hankinson (129) is that 
the reduction work was done aerobically, under which conditions ferrous P450s 
are reoxidized (138). Nishida et al. (5) also emphasized that the conclusion of Bui 
et al. (129-131) that human P450 2S1 normally uses lipid peroxides for catalytic 
function is invalid, in that many P450s can react with lipid hydroperoxides 
through a shunt pathway that generates lipid alkoxy and peroxy radicals. These 
radicals can enter co-oxidation reactions outside of P450 active sites (139, 140). 
In another publication, Bui et al. (131) reported the isomerization activity of P450 
2S1 in a NADPH-independent manner. However, such isomerization activity has 
been seen with several other P450 enzymes and its physiological role still to be 
validated (141-143).  
In conclusion, our results are in agreement with previous findings (5) that 
human P450 2S1 can accept electrons from NADPH-P450 reductase. A 
physiological role of human P450 2S1, if one exists, remains to be revealed.  
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CHAPTER III 
 
FUNCTIONAL ANNOTATION OF ORPHAN HUMAN P450 2W1, 2S1, AND 4X1 
BY METABOLOMIC APPROACHES  
 
Introduction 
Although the genomic sequences of human and numerous other 
organisms have been established, the functions of less than one-half of the 
proteins have been annotated, even in E. coli. Thus, an important and 
challenging task in modern biochemistry is the annotation of protein functions, 
including the establishment of the catalytic activities of novel enzymes with 
unknown substrates (144, 145). P450 enzymes play important roles in the 
metabolism of a large number of compounds, including sterols, fatty acids, 
eicosanoids, vitamins, and xenobiotics (63). It has been estimated that P450 
reactions are involved in ~75% of the enzymatic transformations of small 
molecule drugs (21, 23). There are 57 human P450 genes identified in the 
human genome, and about one fourth of them can be termed “orphans” because 
of their unknown physiological or other functions (20, 21).   
LC-MS is one of the most widely used analytical methods for metabolomic 
analysis and has proved to be a powerful approach in substrate searches (68, 
71, 75, 76). The most commonly used method is to compare incubation mixture 
with and without the functional enzyme or co-factors to identify any changes. 
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Accumulated chemical features after incubation are potential products (68-71). 
Recently we have developed a general strategy for the identification of 
endogenous substrates of human P450s in tissue extracts using LC-MS assays 
and the program DoGEX (14, 85). The approach is based on the fact that the 
majority of P450-mediated reactions involve the incorporation of an oxygen atom 
into the substrate (i.e., the product is 16 amu heavier than the substrate). 
Incubation of a 1:1 mixture of 18O2 and 16O2 gas with tissue extracts generates 
products as M/M+2 doublets in the MS spectra, which can be identified by the 
program DoGEX (14, 85). This strategy has been validated (14) and used to 
identify endogenous substrates for P450 4F11 (64).  
The aim of this study was to identify endogenous substrates for orphan 
human P450 2W1, 2S1, and 4X1. Purified enzyme was used to conduct 
untargeted substrate searches with tissue extracts (i.e., site of P450 expression) 
using either XCMS analysis (69-71) or an isotopic labeling approach (14, 64, 68-
71). A series of lysophospholipids and FFAs were identified as novel substrates 
for P450 2W1, and the isomer- and enantiomer-selectivity of P450 2W1-
catalyzed lysophospholipid oxidations have been characterized. The identities of 
the oxidation products were defined, and steady-state kinetics of the P450 
reactions was determined. No endogenous substrate has been identified for 
human P450 2S1 or 4X1. 
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Experimental procedures 
Materials and reagents 
Human P450s 1A2 (97), 2A6 (146), 2C8 (147, 148), 2D6 (149), 2E1 (102), 
2S1 (36), 2W1 (36), 3A4 (101), 7A1 (150), 4X1 (41), and rat NADPH-P450 
reductase (132) were expressed in E. coli and purified as previously described. 
Human P450 2C19 was expressed (151) and purified using the same protocol as 
that for human P450 2C9 (96). All phospholipids were purchased from Avanti 
Polar Lipids (Alabaster, AL). The BSTFA:TMCS:TMSI:pyridine mixture (3:2:3:10, 
v/v/v/v) was purchased from Regis Technologies (Morton Grove, IL). Preparative 
TLC was conducted on pre-coated 2 mm silica gel GF-254 plates (Analtech, 
Newark, DE). All other reagents and solvents were obtained from general 
commercial suppliers.  
 
Tissue extracts 
Malignant human colorectal cancer samples were obtained from the 
Translational Pathology Shared Resource, Vanderbilt University School of 
Medicine. Human liver and lung samples (from organ donors) were obtained from 
Tennessee Donor Services. Bovine brains were purchased from Pel-Freez 
(Rogers, AR). If not otherwise stated, extracts were prepared from pooled 
samples using Folch reagent (CHCl3:MeOH, 2:1, v/v) as previously described 
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(14). Ethanolic tissue extracts were prepared by homogenizing 20 volumes of 
EtOH with tissues from different brain substructures or pooled human lung/liver 
samples. Tissue homogenate was stirred for 20 min at 23 °C, filtered through 
paper, and dried under a stream of N2.  
 
Enzymatic incubations 
In vitro P450 incubations were performed in 1.0 ml of 100 mM potassium 
phosphate buffer (pH 7.4) each containing purified human P450 enzyme (1.0 
µM), NADPH-P450 reductase (2.0 µM), DLPC (150 µM), an NADPH-generating 
system (3), and an aliquot of an ethanolic solution of tissue extracts (1%, v/v).  
For comparison of enzymatic incubation with and without co-factor (i.e., NADPH-
generating system) by XCMS, incubations were performed in duplicate at 37 °C 
for 30 min. For incubations without the NADPH-generating system, the system 
was added after quenching. Enzymatic incubation mixtures (with tissue extracts 
made with Folch reagent) were quenched with 2 ml of CH2Cl2 and centrifuged at 
3 × 103 g. Lower organic layer was dried under a stream of N2. Enzymatic 
incubation mixtures (with tissue extracts made with EtOH) were quenched with 
MeOH and centrifuged at 3 × 103 g. Supernatant was dried under a stream of N2. 
All samples were redissolved in 100 µl of MeOH, and centrifuged again at 3 × 103 
g followed by LC-MS data collection and data analysis by XCMS. 
For 16O2/18O2 isotopic labeling experiments, reactions were performed 
using the method described previously (14), except that 100% 16O2 and 97% 18O2 
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gas were used in two individual Thunberg tubes. The enzyme reactions were 
initiated by the addition of an NADPH-generating system (3). After incubation at 
37 °C for 60 min, the contents of the two Thunberg tubes were combined (equal 
volumes) and quenched with CH2Cl2 (for incubations with tissue extracts made 
with Folch reagent) or MeOH (for incubations with tissue extracts made with 
EtOH) and centrifuged at 3 × 103 g. Samples was dried under a stream of N2, 
redissolved in 100 µl of MeOH, and centrifuged again at 3 × 103 g for LC-MS 
data collection. The oxidation products were identified as M and M+2 doublets 
(14) with a newly developed approach, which was based on the software 
MZmine2 (79) and an in-house made Matlab program.  
Dansylation was performed as previously described (89) with slight 
modifications. Briefly, samples were dissolved in 200 µl of CH2Cl2 containing 2 
mg of dansyl chloride, 0.5 mg of 4,4-dimethylaminopyridine, and 2 µl of 
triethylamine and heated at 65 °C for 1 h. Each sample was dried under a stream 
of N2 and then dissolved in 100 µl of CH3CN before LC-MS analysis. 
 
LC-MS based metabolomics and data analysis 
LC separation was performed with a Waters Acquity UPLC system 
(Waters, Milford, MA) with an Acquity BEH octadecylsilane (C18) UPLC column 
(1.7 µm, 1.0 mm × 100 mm) at 50°C. Samples (10 µl) were injected onto the 
UPLC column, and components were eluted with a linear gradient increasing 
from 95% (v/v) mobile phase A (10 mM NH4CH3CO2 in a 5:95 (v/v) CH3CN/H2O 
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mixture) to 100% mobile phase B (10 mM NH4CH3CO2 in a 95:5 (v/v) 
CH3CN/H2O mixture) over 20 min, and held at 100% mobile phase B for 5 min at 
a flow rate of 0.15 ml min−1. Data was collected with a ThermoFinnigan LTQ 
mass spectrometer (ThermoFisher, Watham, MA) equipped with an ESI source 
or APCI source scanning from m/z 80 to 800 (profile mode for doublet search; 
centroid mode for XCMS analysis), using the same instrument parameters as 
previously described (14). A ThermoFinnigan Orbitrap mass spectrometer 
(ThermoFisher, Watham, MA) was used for the collection of HRMS data.  
 
Characterization of oxidation products by human P450 2W1 
Characterization of oxidation products was performed by GC-MS after 
preparing the corresponding TMS ethers. Oxidation products of FFAs were 
obtained by incubating each FFA (100 µM) in 1.0 ml of reaction mixture 
containing phosphate buffer, P450 2W1, NADPH-P450 reductase, DLPC, and an 
NADPH-generating system (see above). Each sample was extracted with 2.0 ml 
of CH2Cl2 and dried under a stream of N2. Epoxides were converted to 
dihydrodiols after incubation with H2O (adjusted to pH 2) at 23 °C for 10 min and 
extracted again with CH2Cl2. Oxidation products of lysophosphatidylcholines 
(LPCs) were obtained by incubating each LPC (100 µM) with 1.0 ml of the 
reaction mixture (see above). The reactions were quenched with 2.0 ml of 
CH3OH containing butylated hydroxytoluene (0.005%, w/v) and 1.0 ml of 
aqueous KOH (15%, w/v). The mixtures were then mixed with a vortex device, 
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purged with Ar, and incubated at 37 °C for 30 min to hydrolyze the oxidized LPCs 
and release the oxidized fatty acids (152). The mixtures were acidified to pH 2 
with HCl, and the oxidized fatty acids were extracted into CH2Cl2. TMS 
derivatization was performed with 20 µl of silylation reagent 
(BSTFA:TMCS:TMSI:pyridine, 3:2:3:10, v/v/v/v) at 60 °C for 30 min. The resulting 
TMS derivatives were analyzed with a Finnigan Trace GC DSQ mass 
spectrometer (Thermo Fisher, Watham, MA) using the electron impact negative 
ion mode(14). Samples (4 µL) were injected onto a HP-5 capillary column (30 m 
× 0.25 mm × 0.25 µm, Agilent Technologies, Santa Clara, CA). The temperature 
program started at 150 °C (held for 1 min), and then increased to 300 at 8 °C 
min−1, and held at 300 °C for 6 min more. 
 
Kinetic analysis of P450 2W1-mediated oxidations  
Substrate concentrations ranging from 0 to 200 µM were used for steady-
state kinetic studies. Reactions were run in duplicate at 37 °C for 15 min. 
Oxidation products of FFAs and LPCs were extracted as described above. The 
products were derivatized with 20 µl of 10% (v/v) N,N-diisopropylethylamine in 
CH3CN and 40 µl of 10% (v/v) pFBB in CH3CN at 37°C for 20 min (152). pFBB-
derivatized samples were dried under a N2 stream and then derivatized with 20 µl 
of BSTFA and 7 µl of dry dimethylformamide at 37°C for 20 min (152) and 
analyzed by GC-MS in the chemical ionization mode. FFA C17:0 and C19:0 
standards were used to prepare calibration curves for kinetic analysis of FFA 
  
58 
C16:0 and C18:1 oxidation; 17:0 LPC and C19:0 LPC were used to prepare 
calibration curve for kinetic analysis of 16:0 LPC oxidation. Epoxy-18:1 LPC and 
epoxy-16:1 PC, purified and quantified by a phosphorus assay (153), were used 
to prepare calibration curves for kinetic analysis of 18:1 LPC oxidation. Epoxy-
18:1 LPC was chemically synthesized by incubating 18:1 LPC with an excess 
amount of m-chloroperoxybenzoic acid. The reaction mixture was streaked on a 
preparative fluorescent TLC plate, developed with CH3OH:CHCl3 (1:1 v/v), and 
visualized by UV light. The lower band was scraped and extracted by the same 
solvent, taken to dryness using a rotary evaporator, and dissolved in C2H5OH 
containing 1% diisopropylethylamine (v/v). LC-MS analysis confirmed that all 
18:1 LPC was converted into epoxy-18:1 LPC. Epoxy-16:1 PC was synthesized 
and quantified with the same method (see above). For rate comparisons of 
different lysophospholipids, P450 2W1 was incubated with 100 µM 18:1 LPC, 
18:1 lysophosphatidylinositol (LPI), 18:1 lysophosphatidylserine (LPS), 18:1 
lysophosphatidylglycerol (LPG), 18:1 lysophosphatidylethanolamine (LPE), or 
18:1 lysophosphatidic acid (LPA) in triplicate, and the rates were determined as 
described above.  
 
Purification of sn-1 and sn-2 LPC 
HPLC was used to separate the two isomers. sn-1 and sn-2 LPCs were 
monitored at 196 nm and baseline separation was achieved with a Phenomenex 
prodigy ODS HPLC column (5 µm, 2.0 mm × 150 mm) (154). An isocratic 
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solution of 1:1 (v/v) CH3CN/H2O (pH adjusted to 5 with NH4CO2H) was used to 
resolve the two isomers at 40 °C, at a flow rate of 0.5 ml min−1. The collected sn-
1 and sn-2 LPC fractions were frozen and concentrated by lyophilization prior to 
enzymatic reaction.  
 
Chiral analysis 
Optically pure (9S,10R)- and (9R,10S)-epoxystearic acids were produced 
by hydrogenating pure (9S,10R)-epoxy-12Z-octadecenoic acid and (9R,10S)-
epoxy-12Z-octadecenoic acid (155) with Pd powder under a H2 stream for 3 min 
(14). The enantiomers of 9,10-epoxystearic acid were separated by normal 
phase HPLC with a Waters Alliance 2695 HPLC pump (Waters, Milford, MA) and 
a Chiralpak AD column (5 µm, 4.6 mm × 25 cm). An isocratic solvent of a 
100:2:0.05 (v/v/v) hexanes/CH3OH/CH3CO2H mixture was used to resolve the 
enantiomers at a flow rate of 1 ml min−1 at room temperature. The retention times 
of (9S,10R)- and (9R,10S)-epoxystearic acids were determined to be 16.9 min 
and 18.7 min, respectively. Epoxide generated from FFA C18:1 was extracted 
with CH2Cl2 after enzymatic reaction. Epoxide generated from 18:1 LPC was 
subjected to hydrolysis as described above, and five volumes of 1 M potassium 
phosphate buffer (pH 7.4) was added to neutralize the pH before extraction with 
CH2Cl2. After dried under a N2 stream, the epoxide was analyzed as described 
above and detected with the ESI negative ion mode.  
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Other methods 
UV-visible spectra were recorded using an Aminco DW-2a/OLIS 
spectrophotometer. P450 concentrations were estimated spectrally as previously 
described (3). 
 
Results 
New approach for doublet searches 
A new approach for doublet searches was developed based on the 
MZmine2 software and an in-house made Matlab program. It has improved 
performance regarding both precision and recall compared with the previously 
described DoGEX program (85), although the results cannot be displayed as 
heat maps. LC-MS raw data files were imported to MZmine2. After 
chromatogram construction and deconvolution (79), the data is displayed as a 
peak list, which includes the m/z value, retention time, duration, and peak height 
of individual peaks. The peak list is copied to an Excel file and exported as a 
CSV (Comma Separated Values) file. A Matlab program was developed to 
extract peak information from the CSV file and search for doublet patterns. 
A data file generated from incubation of human P450 2C8 with human 
liver extracts, an NADPH generating system (3), and 16O2/18O2 gas—for which 
number of doublets was already known due to previously reported P450 
reactions (14)—was used to set up parameters (e.g., peak intensity threshold) so 
that as many doublets can be identified as possible. Two peaks would be 
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identified as a doublet if they fit the following criteria: mass difference of 1.9-2.2 
Dalton, retention time difference <1.5 s, height ratio of 0.67-1.5, peak height 
>1000 (arbitrary units), and duration >1 s. To compare the performance of the 
new approach with the previously reported DoGEX program, two data files (P450 
2C8 incubated with liver extracts and 16O2/18O2 gas, and P450 7A1 incubated 
with liver extracts and 16O2/18O2 gas, followed by dansylation (89)) were analyzed 
by both approaches and their true-positive rate (TPR) and positive predictive 
value (PPV) were calculated as follows (156): 
 
TPR = 
FN  TP
TP
+
 
PPV = 
FP  TP
TP
+  
 
Where TP (true-positive) is the percentage of hits identified by the 
software and confirmed in Qual Browser (Thermo Fisher, Watham, MA), FP 
(false-positive) is the percentage of hits that does not share the features of 
doublets, and FN (false-negative) is the number of hits that were not identified by 
the software but yet they are true doublets generated from P450 enzyme -
catalyzed oxidation reactions. TPR is called “recall” and PPV is called “precision”.  
Unlike DoGEX, which uses profile data during the entire data processing 
procedures, the new approach uses deconvoluted data before searching for 
doublets, and therefore many false-positives (from intensities of peak shoulders) 
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can be avoided. The new software performs better in both precision and recall 
(Table 3).  
 
 
 
 
  2C8 data 7A1 data 
New approach 
Precision 11.4 % 25 % 
Recall 100 % 100 % 
DoGEX 
Precision 1.1 % 0.8 % 
Recall 75 % 100 % 
 
Table 3. Comparison of doublet search approaches. 
 
 
Searches for P450 2W1 substrates in malignant human colorectal cancer 
extracts 
Purified P450 2W1 was incubated with malignant human colorectal cancer 
extracts, an NADPH generating system (3), and 16O2/18O2 gas mixtures. In 
principle, all doublets (m/z M/M+2) in LC-MS data result from the addition of an 
oxygen atom to endogenous substrates, with the general concept described 
previously (85). To profile as many metabolites as possible, samples were 
analyzed with both ESI and APCI sources in both the positive and negative 
ionization modes.  
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The doublets m/z 538/540 (Figure 15) in the ESI positive ion mode and 
m/z 269/271, 271/273, 295/297, 297/299, and 319/321 in the ESI negative ion 
mode were identified (Table 4). Product candidates were found only in the 
samples incubated with P450 2W1, NADPH-P450 reductase, and NADPH-
generating system but not in the samples absent any of these. All doublets were 
further confirmed to be oxidation products by comparison with the incubations 
done only with 16O2 gas, in which the m/z M+2 peaks were absent.  
The m/z values of the respective substrates can be deduced from the m/z 
values of the products by subtracting 16 amu (oxygen). Therefore, the molecular 
masses of the putative substrates were calculated to be 521, 254, 256, 280, 282, 
and 304. MS fragmentation of the m/z 538 ion in the ESI positive ion mode 
produced a daughter ion of m/z 184 (Figure 15), indicative of a phosphocholine 
group (157). The LIPIDMAPS database (http://www.lipidmaps.org) suggested 
that 18:1 LPC (m/z 521) was a likely substrate. MS fragmentation analysis of the 
products detected in the ESI negative ion mode and the search of LIPIDMAPS 
database suggested that FFAs C16:0, C16:1, C18:1, C18:2, and C20:4 were 
likely substrates. To confirm the identities of the substrates, 18:1 LPC and five 
FFAs were incubated with P450 2W1 and NADPH, and the extracted products 
were analyzed by LC-MS/MS. All of the product peaks formed in the incubations 
with the authentic compounds yielded exactly the same peaks identified by the 
new software system. These results identified 18:1 LPC and the C16:0, C16:1, 
C18:1, C18:2, and C20:4 FFAs as substrates for P450 2W1 in malignant human 
colorectal cancer tissue. 
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ID mass (m/z) tR (min) intensity   ID mass (m/z) tR (min) intensity 
Identified in the ESI negative ion mode 
6099 269.17 9.76 3554  1748 271.25 9.78 4001 
6091 269.17 8.36 4387  19 271.17 8.37 3216 
4236 269.17 10.01 2612  20 271.17 9.99 2744 
6098 269.17 9.60 9022  1747 271.17 9.61 6466 
3437 269.25 10.59 4499  5748 271.17 10.58 3020 
1740 271.25 9.04 20985  7446 273.25 9.05 14853 
1739 271.17 8.88 1873  4228 273.17 8.88 1328 
10838 295.25 10.44 6876  2795 297.25 10.46 7904 
2793 297.25 10.20 18480  6803 299.25 10.20 13914 
7957 297.25 11.15 19947  9905 299.25 11.15 17247 
7959 297.25 11.32 113883  9907 299.25 11.32 103711 
203 319.17 10.54 1037  3414 321.25 10.55 1329 
 
Identified in the ESI positive ion mode 
12861 538.33 10.12 7169  16842 540.33 10.12 6923 
5691 538.33 9.36 8220   21497 540.25 9.35 6262 
 
Table 4. Doublets identified by Matlab program and confirmed in Qual 
Browser. 
 
 
 
XCMS analysis with P450 2W1 incubating mixtures with and without 
NADPH-generating system (3) identified the accumulation of oxidation products 
from C16:0, C16:1, C18:1, C18:2, and C20:4 FFAs, but not the accumulation of 
the oxidation product of 18:1 LPC. A signal decrease in C16:0, C16:1, C18:1, 
C18:2, and C20:4 FFAs as well as in 18:1 LPC was not observed by XCMS nor 
by manual inspections with LC-MS data in Qual Browser. 
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Dansylation followed by enzymatic incubation (for XCMS and for doublet 
searches) did not identify extra substrate. 
 
Searches for human P450 2S1 substrates in human lung extracts 
Both XCMS and doublet searches were conducted to identify endogenous 
substrate for human P450 2S1 in human lung extracts. Dansylation was also 
used to improve the sensitivity towards unactivated alcohols. However, no 
candidate was identified as a potential substrate or product. 
 
Searches for human P450 4X1 substrates in bovine brain extracts, human 
liver extracts, and human lung extracts 
Both Folch reagent and EtOH were used to make tissue extracts to 
expand compound diversities. Extracts were made with bovine brain samples, 
human liver samples, and human lung samples. In order to preserve the 
compound diversity in ethanolic extracts, enzymatic incubation mixtures with 
ethanolic tissue extracts were quenched with MeOH for LC-MS analysis (protein 
was removed by centrifugation).    
Both XCMS and doublet searches were conducted to identify endogenous 
substrate for human P450 4X1. Dansylation was also used to improve the 
sensitivity towards unactivated alcohols. However, no candidate was identified as 
a potential substrate or product. 
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Figure 15. LC-MS/MS analysis of the m/z 538/540 doublet.  
(A) HRMS of m/z 538/540 produced from the incubation of P450 2W1, NADPH, 
colon cancer extracts, and 18O2/16O2 gas (1:1, v/v). (B) MS/MS fragmentation of 
the 18:1 LPC oxidation product m/z 538 in the ESI positive ion mode. 
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Specificity of 18:1 LPC as a substrate for other human P450 enzymes 
The specificity of 18:1 LPC as a substrate for different human P450 
enzymes was investigated. 18:1 LPC was incubated with purified human P450s 
1A2, 2A6, 2C8, 2C19, 2D6, 2E1, 2S1, 2W1, 3A4, and 7A1, and the extracted 
products were analyzed by LC-MS (Figure 16). Although many other human 
P450 enzymes share similar catalytic efficiencies toward fatty acids (14, 64), they 
showed little activity with 18:1 LPC. We conclude that 18:1 LPC is a substrate 
relatively specific for P450 2W1. 
 
 
Figure 16. Specificity of 18:1 LPC as a substrate for human P450 enzymes.  
Selected ion chromatograms of 18:1 LPC oxidation products (m/z 538) after 
incubating 18:1 LPC with purified P450 enzymes. Retention times (tR) are 
indicated on the chromatograms. 
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Characterization of oxidation products 
 
GC-MS assays of TMS derivatives were used to characterize the oxidation 
products of P450 2W1 reactions. For FFAs, oxidation products were extracted 
with CH2Cl2 and their identities were established after silylation. For LPCs, base 
hydrolysis was performed to release the oxidized fatty acids prior to silylation. 
Multiple doublets in the LC-MS data shared the same m/z, suggesting that each 
substrate may have multiple products (Figure 16). As summarized in Table 5 and 
Figure 17, P450 2W1 catalyzed both hydroxylation and epoxidation in the middle 
of fatty acid chains. 
 
Steady-state kinetic analysis of P450 2W1 reactions 
Kinetic studies were performed for 16:0 LPC and 18:1 LPC, as well as for 
the FFAs C16:0 and C18:1. The kinetic parameters kcat and Km were estimated 
based on Michaelis-Menten plots and nonlinear regression analysis (Table 6). 
The catalytic efficiencies (kcat/Km) of P450 2W1-catalyzed fatty acid oxidations 
were comparable with those catalyzed by other human P450 enzymes (14, 64). 
The catalytic efficiency of 18:1 LPC oxidation was ∼6-fold greater than that of the 
FFA C18:1. 
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Substrate  [M+•] Major fragment ions (m/z) Product 
16:01, 2 Hydroxylation 416 145, 159, 173, 345, 359, 373 11-OH, 12-OH, 13-OH 
18:11, 2 Hydroxylation 442 201, 241, 303, 343 8-OH, 11-OH 
18:11, 2 Epoxidation 532 215, 317 9, 10-epoxide 
16:0 LPC1 Hydroxylation 416 215, 229, 243, 275, 289, 303 6-OH, 7-OH, 8-OH 
18:0 LPC1 Hydroxylation 444 229, 243, 257, 289, 303, 317 7-OH, 8-OH, 9-OH 
18:1 LPC1 Hydroxylation 442 201, 241, 303, 343 8-OH, 11-OH 
18:1 LPC1 Epoxidation 532 215, 317 9, 10-epoxide 
20:0 LPC1 Hydroxylation 472 243, 257, 271, 303, 317, 331 8-OH, 9-OH, 10-OH 
 
 
Table 5. EI GC-MS analysis of TMS derivatives of the oxidation products of 
fatty acids and LPCs by human P450 2W1. 
1 See Figure 17 for fragmentation patterns. 
2 FFA 
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Figure 17. EI GC-MS fragmentation patterns of TMS-derivatized oxidized 
fatty acid moieties. 
Oxidized fatty acid moieties from enzymatic incubations with P450 2W1 with (A-
C) C16:0, (D-F) C18:1, (G-I) C16:0; after incubation and base hydrolysis with (J-
L) 18:0 LPC, (M-O) 18:1 LPC, and (P-R) 20:0 LPC. 
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Substrate   kcat (min−1) Km (µM) kcat/Km (min−1 mM−1) 
16:01 Hydroxylation 0.77 ± 0.06 83 ± 17 9.3 ± 0.7 
18:11 Hydroxylation 0.63 ± 0.09 101 ± 31 6.2 ± 0.9 
18:11 Epoxidation 0.044 ± 0.003 95 ± 13 0.46 ± 0.03 
16:0 LPC Hydroxylation 0.012 ± 0.002 14 ± 5 0.9 ± 0.1 
18:1 LPC Hydroxylation 1.36 ± 0.16 38 ± 12 36 ± 4 
18:1 LPC Epoxidation 0.21 ± 0.02 34 ± 11 6.2 ± 0.6 
 
Table 6. Steady-state kinetics of P450 2W1-catalyzed oxidations 
1 FFA 
 
 
 
Isomer specificity of lysophospholipid oxidation 
Commercially available LPCs are mixtures of both sn-1 and sn-2 isomers 
due to acyl migration, which occurs even at neutral pH (158). The inter-
conversion can be attenuated at pH 4–5 (158), and baseline separation could be 
achieved using a pH 5 solvent in HPLC (Figure 18). The identities of recovered 
isomers were confirmed by MS/MS fragmentation patterns, due to the different 
ratios of fragmentation ions at m/z 184 and 104 (157): the sn-1 isomer produces 
(Figure 19, D, E) more m/z 104 daughter ion than the sn-2 isomer (Figure 15, B). 
A mock incubation of pure sn-1 and sn-2 isomers in a P450 reaction mixture was 
performed for 10 min, and little inter-conversion between the two isomers was 
observed. To determine the isomer specificity of lysophospholipid oxidation, 
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equivalent amounts of sn-1 and sn-2 isomers were incubated with P450 2W1 and 
NADPH for 10 min. The reactions were quenched with three volumes of CH3CN, 
and the pH was decreased to 5 with one-half volume of 1 M NH4CO2H buffer (pH 
5). Oxidation of 18:1 LPC was observed only in the incubation with sn-1 isomer 
(Figure 19). The sn-1 isomeric nature of the oxidation product, confirmed by 
MS/MS fragmentation (Figure 19), also indicated that sn-1 18:1 LPC is the 
preferred substrate. We conclude that the sn-1 isomers of lysophospholipids are 
preferred substrates. 
 
 
 
 
 
 
Figure 18. Baseline separation of sn-1 and sn-2 isomer of 18:1 LPC. 
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Figure 19. Isomer specificity of lysophospholipid oxidation.  
Selected ion chromatograms of 18:1 LPC oxidation products (m/z 538) after 
incubating P450 2W1 with (A) sn-1 18:1 LPC, (B) sn-2 18:1 LPC, or (C) an 
equilibrated mixture of sn-1 and sn-2 18:1 LPC (containing 90% sn-1 18:1 LPC 
and 10% sn-2 18:1 LPC). Fragmentation of (D) the peak at tR 11 min and (E) the 
peak at tR 12 min. 
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Substrate specificity for other phospholipids 
Diacylphospholipids, including 16:0 PC, 16:0-18:1 PC, and 16:0-20:4 PC, 
were incubated with the P450 2W1 reaction mixture and analyzed using the 
same conditions as for LPCs; no oxidation products were detected. Other 
classes of lysophospholipids, including 18:1 LPI, 18:1 LPS, 18:1 LPG, 18:1 LPE, 
and 18:1 LPA, were also confirmed to be substrates for P450 2W1, with similar 
rates of oxidation (Figure 20). 
 
 
Figure 20. Rates of P450 2W1-catalyzed oxidation with different 18:1 
lysophospholipids. 
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Chiral analysis 
P450 2W1-catalyzed epoxidation was investigated with chiral HPLC. The 
epoxide generated from FFA C18:1 was a mixture of (9S,10R) and (9R,10S) in 
the molar ratio of 1:10 (Figure 21). The epoxide generated from 18:1 LPC was 
extracted after hydrolysis, and chiral analysis showed that epoxy-18:1 LPC was 
also a mixture of (9S,10R) and (9R,10S) but in the ratio of 1:3 (Figure 21). 
 
 
 
Figure 21. Chiral analysis of P450 2W1-catalyzed epoxidation of FFA C18:1 
and 18:1 LPC.  
Selected ion chromatograms of P450 2W1-catalyzed epoxidations (m/z 297 > 
171) of (A) FFA C18:1 (B) 18:1 LPC. The identity of the peak at tR 16.5 min is 
unknown. 
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Discussion 
To elucidate the substrate specificities and possible physiological 
functions of human P450 2W1, 2S1, and 4X1, untargeted substrate searches 
were performed using XCMS (76) and an LC-MS-based metabolomic and 
isotopic-labeling approach (14, 68-71, 85). In addition to FFAs, 18:1 LPC was 
identified as a substrate for P450 2W1 (Table 4). Other human P450 enzymes 
tested showed little activity toward 18:1 LPC (Figure 16). In addition to LPCs, a 
series of other lysophospholipids, including 18:1 LPI, 18:1 LPS, 18:1 LPG, 18:1 
LPE, and 18:1 LPA (but not diacylphospholipids), were identified as substrates 
for P450 2W1 (Figure 20). sn-1 18:1 LPC was the preferred substrate over the 
sn-2 isomer (Figure 19), and we conclude that the sn-1 isomers of 
lysophospholipids are the preferred substrates. For the 18:1 epoxidation product, 
chiral analysis showed enantio-selectivity for formation of (9R,10S) over 
(9S,10R). The position specificities (Figure 21) and the kinetics (Table 6) of P450 
2W1-catalyzed oxygenation of lysophospholipids (16:0 LPC and 18:1 LPC) and 
FFAs (C16:0 and C18:1) were also determined. The epoxidation and 
hydroxylation for 18:1 LPC were considerably more efficient than for the FFA 
C18:1. The reaction with an unsaturated acyl LPC (18:1 LPC) was also 
considerably more efficient than with a saturated acyl LPC (16:0 LPC). No 
endogenous substrate was identified for human P450 2S1 or 4X1. 
Different extraction methods could enrich different classes of compounds. 
Most substrate and product of P450 enzymes are hydrophobic and can be 
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extracted by CH2Cl2 and Folch reagent. To increase the compound diversity in 
the tissue extracts, EtOH can be used to include more hydrophilic compounds. 
However, caution must be taken in that more compounds in tissue extracts could 
be a burden for analytical instruments, and signals from unrelated compounds 
could potentially mask the signals from substrates or products of the enzyme. To 
date, no successful example has been reported for a P450 enzyme for which an 
additional substrate has been identified with an ethanolic tissue extract.   
FFAs are common substrates for a number of human and other P450 
enzymes (36, 39, 42, 64, 159). Among the five fatty acids identified in our study, 
only C20:4 has been reported as a substrate for P450 2W1 previously (36). This 
is the first report that the FFAs C16:0, C16:1, C18:1, and C18:2 are substrates 
for P450 2W1. P450 2W1 catalyzes both hydroxylation and epoxidation at the 
middle of fatty acid chains (Table 5). Although some of oxidation products of 
FFAs have been shown to have interesting physiological functions in vivo (160), 
the fact that many P450 enzymes catalyze FFA oxidations at very slow rates 
raises doubts about the physiological importance of many of the products (e.g., 
ω-1, ω-2).  
To my knowledge, this is the first report that lysophospholipids are 
substrates for any P450 enzyme. The most abundant LPCs in plasma are 16:0 
LPC, 18:0 LPC, 18:1 LPC, 18:2 LPC, and 20:4 LPC (161). All of these, except 
18:2 LPC and 20:4 LPC, were confirmed to be substrates for P450 2W1. 18:2 
LPC and 20:4 LPC are also likely to be substrates for P450 2W1, but these were 
not commercially available and, therefore, were not tested. The results of these 
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kinetic studies suggest that unsaturated acyl LPCs are more efficiently oxidized 
by P450 2W1 than are saturated acyl LPCs.  
Although commercial LPCs are composed of ∼90% sn-1 and ∼10% sn-2 
isomers, the percentage of each isomer in plasma has been reported to be ∼50% (162). In plasma, 90% of the unsaturated acyl LPCs were sn-1 isomers 
(162), which can be more efficiently oxidized by P450 2W1 compared with 
saturated acyl LPC.  
Lysophospholipids are lipid mediators involved in a vast variety of 
biological functions (163). In particular, LPCs are endogenous proinflammatory 
lipids that stimulate chemo taxis of T lymphocytes (164) and macrophages (165). 
Decreased concentrations of LPCs have been identified in the plasma of 
colorectal cancer and lung cancer patients (157, 166). Thus, decreased LPC 
levels may be an important contributing factor for tumor development. LPAs are 
also potent lipid mediators that lead to a plethora of biological actions, including 
cell proliferation, survival, motility, and invasion, which are critically required for 
tumor initiation and progression (167, 168). 18:1 LPA, one of the substrates of 
P450 2W1, has been reported to enhance the metastatic potential of human 
colon cancer cells and to protect them from apoptosis (169-171). One aspect of 
LPA action is its role as a ligand for several cell surface G-protein coupled 
receptors [e.g., LPA1, LPA2, LPA3, LPA4/GPG23, and LPA5/GPR92 (172)]; it is 
not known whether these receptors are isomer-selective or enantio-selective. 
LPA enhances cell proliferation by activation of the transcription factor Krüppel-
like fractor 5 (KLF5) (170, 173). Considering the presence of hydroxyl- and 
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epoxy-lysophospholipids/phospholipids in vivo (174, 175), it is possible that P450 
2W1-catalyzed lysophospholipid oxidations are involved in inflammation and 
tumor development by producing ligands to these receptors and modulate 
downstream signaling pathways, although further information is not available.  
The balance of concentrations of oxidized lysophospholipids is very delicate. 
They can be synthesized from at least three pathways: P450 2W1-catalyzed 
lysophospholipid oxidation, deacylation from oxidized phospholipids (175), and 
esterification of oxidized fatty acids to the glycerol derivatives. At the meantime, 
they can be degraded by several lysophospholipase-based pathways. It is 
possible that the upregulation of P450 2W1 expression in colorectal cancer 
tissues disturbs the balance of oxidized lysophospholipids and leads to 
pathological consequences, but further conjecture about the role of P450 2W1 in 
cancer is speculative.  
In conclusion, we have identified P450 oxidation reactions that selectively 
occur on lysophospholipid fatty acid chains (but not on diacylphospholipids). 
They were found to be selectively catalyzed by an orphan human P450, P450 
2W1, that had not been clearly shown to have definitive catalytic activities with 
physiological substrates previously. The physiological functions of these oxidized 
lysophospholipids, if any, remain to be established. We have also introduced new 
software for the analysis of isotopic compositions of compounds in MS, which 
can be used in other metabolomic studies. No endogenous substrate was 
identified for human P450 2S1 or 4X1. 
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CHAPTER IV 
 
HETEROLOGOUS EXPRESSION OF HUMAN P450 ENZYMES 
 
Introduction 
Historically, human P450 enzymes were isolated from human tissue 
samples (52). However, due to the difficulties in obtaining human samples and in 
purifying specific P450 enzyme without cross-contamination from others, the 
establishment of heterologous expression systems has been used as a popular 
alternative to obtain active P450 enzymes for functional studies.  
Among the orphan human P450 enzymes covered in this thesis work, 
human P450 2S1 and 2W1 have been expressed and purified in E. coli 
expression systems with good yields (36). Human P450 4V2 was expressed and 
purified from insect cells, but the expression level was low (~ 50 nM) (42). 
Human P450 2U1 and 4Z1 have been expressed either in E. coli (37), insect 
cells (39), or yeast (40). However, the expression levels were not satisfactory.  
This chapter describes the establishment of heterologous protein 
expression systems to obtain active human P450 enzymes for future functional 
studies. Heterologous expressions of P450 46A1 and orphan P450 2U1, 4V2, 
and 4Z1 have been tested in E. coli expression systems. Codon-optimization 
tremendously increased the expression levels of P450 46A1 and P450 2U1. 
Baculovirus expression systems were tested for P450 4V2 and 4Z1 after the 
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failure in E. coli expression systems. Expressions of P450 4V2 and 4Z1 in insect 
cells were achieved with low yields. Co-expressions of P450 4V2/4Z1 with 
NADPH-P450 reductase were achieved in insect cells, and the isolated 
membrane fractions can be used for future functional studies. 
 
Experimental procedures 
Materials and reagents 
Codon-optimized coding sequences for heterologous expressions in E. 
coli systems (i.e., P450 2U1, 4V2, 4Z1, and 46A1) were designed with DNA 2.0 
technology (106) or IDT (107), and synthesized either in-house (36, 38) or by 
Genewiz, NJ) (36). Native coding sequences for heterologous expressions in 
insect cells were obtained from DF/HCC DNA Resource Core (Harvard, Boston). 
The baculovirus IRES sequence was generously provided by Dr. Tzong-Yan Wu 
(National Tsing Hua University, Hsinchu, Taiwan, ROC). All other reagents, 
solvents, and competent cells were obtained from general commercial suppliers.  
 
Heterologous expressions in E. coli cells  
Expression vectors were constructed with codon-optimized coding 
sequences and a His6-tag at C-terminal. Expression trials were conducted as 
previously described (36) at 23 °C or 28 °C with different E. coli strains (i.e., 
DH5α, BL21 DE3, BL21 DE3 pLyss, TOP10, XL1-Blue, XL10-Blue, and C41) 
with and without the co-expression of different chaperones (i.e., pG-KJE8, 
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pGro7, pKJE7, pTf16, pACYC). P450 spectra were measured 24, 48, and 72 h 
after induction.  
 
Heterologous expressions in insect cells  
Expression vectors (pFastbac and pFastbac-dual) were constructed with 
native coding sequences and a His6-tag at C-terminal. Insect cells (i.e., sf9 and 
sf21 cells) were maintained in spinner flasks in Sf-900 III SFM media containing 
5% fetal bovine serum (v/v). The expression culture was supplemented with 0.3 
mM δ-aminolevulinic acid and 0.2 mM ferric citrate 24 h post infection with the 
recombinant virus. Cells were harvested 48 and 72 h post infection, followed by 
the isolation of microsomal fraction and collection of P450 spectra with the 
method described (42). 
 
Other methods 
Immunoblotting was conducted with the method described (83). UV-visible 
spectra were recorded using an Aminco DW-2a/OLIS spectrophotometer. P450 
concentrations were estimated spectrally as previously described (153). Methyl 
viologen (final concentration 1.2 µM) was used in the measurement of human 
P450 4V2 and 4Z1 expressed in insect cells. 
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Results 
Previous expression trials of P450 4Z1 in E. coli expression systems  
Dr. Zhongliu Wu and Dr. G. Salamanca-Pinzón tested several N-terminal 
modifications with a codon-optimized 4Z1 sequence but no satisfactory 
expression level could be obtained (data not shown) (Table 7). 
 
 
Constructs  N-terminal Amino Acid Sequences  
4Z1 native  MEPSWLQELMAHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAH  
Wu #1  MALLLAVFLQELMAHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAH 
Wu #2  MALLLAVFLMAHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAH 
Wu #3  MAHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAH 
Wu #4  MALLLAVFLRLYQRRRWMIRALHLFPAPPAH  
Wu #5  MAKKTSSKGKLYQRRRWMIRALHLFPAPPAH  
Wu #6  MALLLFQVIRLYQRRRWMIRALHLFPAPPAH  
Wu #7 MARQSFGRGKLPAPPAH  
Wu #8  MAKKTSSKGKLPAPPAH  
Salamanca #2 MARQVHSSWNLHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAH 
Salamanca #3 MAKKTSSKGKLHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAH 
Salamanca #4 MAKKTSSKGRLQVIRLYQRRRWMIRALHLFPAPPAH 
Salamanca #5 MAQVIRLYQRRRWMIRALHLFPAPPAH 
Salamanca #6 MAKKTSSKGKLPAPPAH 
 
Table 7. Previously tested N-terminal modification for 4Z1 expression.  
Eight were tested by Dr. Zhongliu Wu (Wu # 1-8); five were tested by Dr. G. 
Salamanca-Pinzón (Salamanca # 2-6). Underlined letters are different N-terminal 
modifications. 
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Expression trials of P450 4Z1 with new N-terminal modifications  
New N-terminal modifications (Table 8) were designed with the codon-
optimized 4Z1 sequence. Expression trials were conducted with different E. coli 
strains (DH5α, DH5α F’IQ, BL21 DE3, BL21 DE3 pLyss, TOP10, XL1-Blue, 
XL10-Blue, and C41) and co-expression of different chaperones (pG-KJE8, 
pGro7, pKJE7, pTf16, pACYC) at 23 °C or 28 °C after induction. Reproducible 
P450 spectra (Figure 22) that indicate an expression level of 300 nM with crude 
cell culture could be obtained with construct # 4 in DH5α cells 48 h after induction 
with the co-expression of GroES/EL. However, no P450 spectrum could be 
observed in the membrane or cytosol fractions (data not shown).  
 
 
 
 
Table 8. New N-terminal modifications for heterologous expression of P450 
4Z1 in E. coli.  
Underlined letters are different N-terminal modifications. 
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Figure 22. P450 spectrum of expressed human P450 4Z1 from E. coli cells. 
With construct # 4 in DH5α cells 48 h after induction with the co-expression of 
GroES/EL. The calculated concentration of P450 4Z1 was 300 nM with crude cell 
culture. 
 
 
 
Troubleshooting P450 4Z1 expression in E. coli expression systems 
Quantitative immunoblotting was performed to quantify the expression of 
P450 4Z1 protein in the membrane fraction. Although the immunoblotting result 
indicates a high concentration of P450 4Z1 (~ 5 µM) in the membrane fraction 
(Figure 23), no P450 spectrum can be observed (data not shown). Thus, two 
possibilities were speculated: 1) P450 4Z1 polypeptide was translated and was 
detected by the anti-His6-tag antibody, but no active protein was generated 
(possibly due to misfolding or difficulty in heme incorporation); 2) active P450 
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4Z1 was generated but the catalytic activity was lost quickly during membrane 
isolation. Since it is technically challenging to address either possibility, a 
baculovirus expression system was tested to obtain functional P450 4Z1. 
 
 
 
 
Figure 23. Quantitative immunoblotting to detect P450 4Z1 expression. 
Lanes 1, 2, and 3 were loaded with 0.5, 1, and 2 µl of P450 4Z1-expressed 
membrane fraction. Lanes 7, 8, 9, and 10 were loaded with 0.825 pmol, 1.65 
pmol, 2.475 pmol, and 3.3 pmol of a purified P450 2B6 protein. Protein was 
detected with anti-His6-tag antibody and LI-COR system. The standard curve 
was built based on the signal intensity of purified P450 2B6 protein (shown in the 
bottom right corner). 
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Expression of P450 4Z1 and 4V2 in insect cells  
Mono-cistronic expression vectors for P450 4V2 (previous expression 
trials failed in E. coli expression systems, data not shown) (sequence in Figure 
24) and 4Z1 (sequence in Figure 25) have been constructed with native coding 
sequences. Due to technical difficulties in generating high-titer virus stock in-
house, the isolated baculovirus genome was shipped to the Wistar Institute 
(Philadelphia, PA) to generate high-titer bacoluvirus stock for expression trials. 
No significant difference in expression levels was observed with different insect 
cell stains (sf9 versus sf21) (data not shown). The best expression levels (24 nM 
for P450 4V2; 8 nM for P450 4Z1) were obtained 48 h after infection with a MOI 
of 5 (Figure 26).   
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GAATTCATGGCGGGGCTCTGGCTGGGGCTCGTGTGGCAGAAGCTGCTGCT
GTGGGGCGCGGCGAGTGCCCTTTCCCTGGCCGGCGCCAGTCTGGTCCTGA
GCCTGCTGCAGAGGGTGGCGAGCTACGCGCGGAAATGGCAGCAGATGCG
GCCCATCCCCACGGTGGCCCGCGCCTACCCACTGGTGGGCCACGCGCTGC
TGATGAAGCCGGACGGGCGAGAATTTTTTCAGCAGATCATTGAGTACACAG
AGGAATACCGCCACATGCCGCTGCTGAAGCTCTGGGTCGGGCCAGTGCCC
ATGGTGGCCCTTTATAATGCAGAAAATGTGGAGGTAATTTTAACTAGTTCAA
AGCAAATTGACAAATCCTCTATGTACAAGTTTTTAGAACCATGGCTTGGCCT
AGGACTTCTTACAAGTACTGGAAACAAATGGCGCTCCAGGAGAAAGATGTT
AACACCCACTTTCCATTTTACCATTCTGGAAGATTTCTTAGATATCATGAATG
AACAAGCAAATATATTGGTTAAGAAACTTGAAAAACACATTAACCAAGAAGC
ATTTAACTGCTTTTTTTACATCACTCTTTGTGCCTTAGATATCATCTGTGAAAC
AGCTATGGGGAAGAATATTGGTGCTCAAAGTAATGATGATTCCGAGTATGTC
CGTGCAGTTTATAGAATGAGTGAGATGATATTTCGAAGAATAAAGATGCCCT
GGCTTTGGCTTGATCTCTGGTACCTTATGTTTAAAGAAGGATGGGAACACAA
AAAGAGCCTTAAGATCCTACATACTTTTACCAACAGTGTCATCGCGGAACGG
GCCAATGAAATGAACGCCAATGAAGACTGTAGAGGTGATGGCAGGGGCTCT
GCCCCCTCCAAAAATAAACGCAGGGCCTTTCTTGACTTGCTTTTAAGTGTGA
CTGATGACGAAGGGAACAGGCTAAGTCATGAAGATATTCGAGAAGAAGTTG
ACACCTTCATGTTTGAGGGGCACGATACAACTGCAGCTGCAATAAACTGGT
CCTTATACCTGTTGGGTTCTAACCCAGAAGTCCAGAAAAAAGTGGATCATGA
ATTGGATGACGTGTTTGGGAAGTCTGACCGTCCCGCTACAGTAGAAGACCT
GAAGAAACTTCGGTATCTGGAATGTGTTATTAAGGAGACCCTTCGCCTTTTT
CCTTCTGTTCCTTTATTTGCCCGTAGTGTTAGTGAAGATTGTGAAGTGGCAG
GTTACAGAGTTCTAAAAGGCACTGAAGCCGTCATCATTCCCTATGCATTGCA
CAGAGATCCGAGATACTTCCCCAACCCCGAGGAGTTCCAGCCTGAGCGGTT
CTTCCCCGAGAATGCACAAGGGCGCCATCCATATGCCTACGTGCCCTTCTC
TGCTGGCCCCAGGAACTGTATAGGTCAAAAGTTTGCTGTGATGGAAGAAAA
GACCATTCTTTCGTGCATCCTGAGGCACTTTTGGATAGAATCCAACCAGAAA
AGAGAAGAGCTTGGTCTAGAAGGACAGTTGATTCTTCGTCCAAGTAATGGC
ATCTGGATCAAGTTGAAGAGGAGAAATGCAGATGAACGCCATCATCATCATC
ATCATTAAGTCGAC 
 
Figure 24. Sequence information of P450 4V2 in pFastbac.  
Restriction sites for cloning purpose are shown in Bold. 
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GCGCGCATGGAACCTTCTTGGCTGCAGGAGCTGATGGCACACCCGTTCTTA
CTGCTGATCCTGTTATGTATGAGCCTGCTGTTATTCCAGGTCATTCGTTTATA
TCAGCGCCGTCGCTGGATGATTCGTGCGCTGCATTTATTCCCAGCCCCACC
GGCGCACTGGTTCTACGGCCATAAGGAATTCTACCCGGTGAAGGAGTTTGA
GGTCTATCACAAACTGATGGAGAAATACCCATGTGCGGTTCCGTTATGGGT
CGGTCCATTCACGATGTTCTTCAGCGTTCACGACCCAGATTACGCCAAAATT
CTGTTAAAGCGTCAGGACCCGAAATCTGCGGTGTCTCACAAGATTCTGGAA
AGCTGGGTTGGCCGTGGCCTGGTCACCCTGGACGGTTCTAAATGGAAAAAA
CATCGCCAAATTGTGAAGCCGGGCTTCAACATCAGCATTCTGAAAATCTTCA
TCACCATGATGAGCGAGAGCGTCCGCATGATGCTGAACAAGTGGGAGGAG
CATATTGCGCAGAACAGCCGCCTGGAGCTGTTCCAACACGTCAGCCTGATG
ACGTTAGATAGCATTATGAAATGCGCCTTTAGCCACCAGGGCAGCATCCAA
CTGGACAGCACCTTAGACAGCTACTTAAAGGCCGTGTTTAATCTGAGCAAG
ATTAGCAACCAACGTATGAACAACTTCCTGCACCACAACGACTTAGTGTTCA
AGTTCTCTAGCCAAGGCCAGATTTTTAGCAAGTTTAACCAGGAACTGCATCA
ATTCACCGAAAAGGTCATCCAAGATCGCAAGGAAAGCCTGAAGGACAAGCT
GAAACAGGACACGACGCAAAAGCGCCGCTGGGATTTCCTGGACATTCTGCT
GTCTGCCAAGAGCGAAAACACGAAGGATTTCTCTGAGGCAGATCTCCAGGC
CGAAGTGAAAACCTTCATGTTTGCCGGTCATGATACCACGTCTAGCGCAATT
TCTTGGATCCTGTATTGTCTGGCGAAATACCCGGAACACCAACAGCGTTGC
CGTGATGAAATTCGCGAGTTACTGGGTGACGGCAGCTCTATTACGTGGGAG
CACCTGTCTCAGATGCCATACACGACCATGTGTATTAAGGAATGCCTGCGC
CTGTATGCGCCGGTGGTCAACATCAGCCGCCTGCTGGACAAACCGATCACC
TTTCCAGACGGTCGCAGCCTGCCAGCGGGCATCACCGTCTTTATCAACATT
TGGGCACTGCATCATAACCCATACTTTTGGGAGGACCCGCAAGTGTTTAAC
CCGCTGCGCTTCAGCCGTGAAAATAGCGAGAAGATCCACCCGTATGCGTTC
ATCCCATTTAGCGCAGGTTTACGCAACTGCATTGGCCAGCACTTTGCGATCA
TTGAATGCAAAGTTGCAGTGGCGCTGACCCTGCTGCGTTTCAAGTTAGCGC
CAGATCATAGCCGTCCACCGCAGCCGGTTCGTCAAGTTGTGTTAAAGAGCA
AGAACGGTATCCACGTGTTTGCGAAAAAGGTCTGCCATCACCACCATCATC
ATTAAGTCGAC 
 
Figure 25. Sequence information of P450 4Z1 in pFastbac.  
Restriction sites for cloning purpose are shown in Bold. 
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Figure 26. P450 spectra with P450 4V2 and 4Z1 from insect cells.  
Methyl viologen was added at a final concentration of 1.2 µM. 
 
 
It would be difficult to obtain enough purified protein with the mono-
cistronic expression systems described above. Therefore, systems that co-
express P450 enzyme and NADPH-P450 reductase were tested. If succeeded, 
the isolated membrane fractions can be used for functional assays.  
Several systems can be used to co-express P450 enzyme and NADPH-
P450 reductase: 1) infect insect cells with two strains of virus, one expressing a 
P450 enzyme and the other one expressing NADPH-P450 reductase. However, 
this method is known to cause a huge reduction in expression levels and thus is 
rarely used (115); 2) infect insect cells with a single virus strain with a dual 
promoters system, one promoter expressing NADPH-P450 reductase (sequence 
in Figure 27) and the another one expressing P450 4V2 (sequence in Figure 24) 
or 4Z1 (sequence in Figure 25); 3) infect insect cells with a bi-cistronic virus 
strain, in which one single promoter drives the expression of both the P450 
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enzyme and NADPH-P450 reductase. The coding sequences of two proteins are 
connected with an IRES so that both proteins can be transcribed and translated 
(117). The IRES from E. coli (lg10) and from insect cell virus Rhopalosiphum 
padi (RhPV) were both tested for the co-expression systems (constructed 
sequences in Figures 28-31). No significant difference in expression levels was 
observed with different insect cell stains (sf9 versus sf21) (data not shown). For 
both the dual promoter and bi-cistronic systems, the expression levels of 
NADPH-P450 reductase were ~ 8 nM. The best expression levels of P450 
enzymes (Table 9) were obtained 48 h after infection with a MOI of 5.  
In retrospect there is a missense mutation in the bi-cistronic expression 
vector 4V2-RhPV-IRES-OR (Figure 28).  
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CTCGAGATGGGAGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGC
GGTGGCCGAAGAAGTATCTCTTTTCAGCATGACGGACATGATTCTGTTTTCG
CTCATCGTGGGTCTCCTAACCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAG
AAGTCCCCGAGTTCACCAAAATTCAGACATTGACCTCCTCTGTCAGAGAGA
GCAGCTTTGTGGAAAAGATGAAGAAAACGGGGAGGAACATCATCGTGTTCT
ACGGCTCCCAGACGGGGACTGCAGAGGAGTTTGCCAACCGCCTGTCCAAG
GACGCCCACCGCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTA
TGACCTGGCCGACCTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGG
TTTTCTGCATGGCCACCTACGGTGAGGGAGACCCCACCGACAATGCCCAG
GACTTCTACGACTGGCTGCAGGAGACAGACGTGGATCTCTCTGGGGTCAAG
TTCGCGGTGTTTGGTCTTGGGAACAAGACCTACGAGCACTTCAATGCCATG
GGCAAGTACGTGGACAAGCGGCTGGAGCAGCTCGGCGCCCAGCGCATCTT
TGAGCTGGGGTTGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCA
CCTGGCGAGAGCAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAA
GCCACTGGCGAGGAGTCCAGCATTCGCCAGTACGAGCTTGTGGTCCACAC
CGACATAGATGCGGCCAAGGTGTACATGGGGGAGATGGGCCGGCTGAAGA
GCTACGAGAACCAGAAGCCCCCCTTTGATGCCAAGAATCCGTTCCTGGCTG
CAGTCACCACCAACCGGAAGCTGAACCAGGGAACCGAGCGCCACCTCATG
CACCTGGAATTGGACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGAC
CACGTGGCTGTGTACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGC
AAAATCCTGGGTGCCGACCTGGACGTCGTCATGTCCCTGAACAACCTGGAT
GAGGAGTCCAACAAGAAGCACCCATTCCCGTGCCCTACGTCCTACCGCACG
GCCCTCACCTACTACCTGGACATCACCAACCCGCCGCGTACCAACGTGCTG
TACGAGCTGGCGCAGTACGCCTCGGAGCCCTCGGAGCAGGAGCTGCTGCG
CAAGATGGCCTCCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGCTGGG
TGGTGGAGGCCCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCC
CTGCGGCCCCCCATCGACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGC
CCGCTACTACTCCATCGCCTCATCCTCCAAGGTCCACCCCAACTCTGTGCA
CATCTGTGCGGTGGTTGTGGAGTACGAGACCAAGGCCGGCCGCATCAACA
AGGGCGTGGCCACCAACTGGCTGCGGGCCAAGGAGCCTGCCGGGGAGAA
CGGCGGCCGTGCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTCCGCC
TGCCCTTCAAGGCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGG
GTGGCACCCTTCATAGGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCA
GGGCAAGGAGGTGGGGGAGACGCTGCTGTACTACGGCTGCCGCCGCTCG
GATGAGGACTACCTGTACCGGGAGGAGCTGGCGCAGTTCCACAGGGACGG
TGCGCTCACCCAGCTCAACGTGGCCTTCTCCCGGGAGCAGTCCCACAAGG
TCTACGTCCAGCACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAAGTTGA
TCGAAGGCGGTGCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCC
AGGGATGTGCAGAACACCTTCTACGACATCGTGGCTGAGCTCGGGGCCAT
GGAGCACGCGCAGGCGGTGGACTACATCAAGAAACTGATGACCAAGGGCC
GCTACTCCCTGGACGTGTGGAGCTAGGCTAGC 
 
Figure 27. Sequence information of NADPH-P450 reductase in pFastbac-
dual.  
Restriction sites for cloning purpose are shown in Bold. 
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GAATTCATGGCGGGGCTCTGGCTGGGGCTCGTGTGGCAGAAGCTGCTGCT
GTGGGGCGCGGCGAGTGCCCTTTCCCTGGCCGGCGCCAGTCTGGTCCTGA
GCCTGCTGCAGAGGGTGGCGAGCTACGCGCGGAAATGGCAGCAGATGCG
GCCCATCCCCACGGTGGCCCGCGCCTACCCACTGGTGGGCCACGCGCTGC
TGATGAAGCCGGACGGGCGAGAATTTTTTCAGCAGATCATTGAGTACACAG
AGGAATACCGCCACATGCCGCTGCTGAAGCTCTGGGTCGGGCCAGTGCCC
ATGGTGGCCCTTTATAATGCAGAAAATGTGGAGGTAATTTTAACTAGTTCAA
AGCAAATTGACAAATCCTCTATGTACAAGTTTTTAGAACCATGGCTTGGCCT
AGGACTTCTTACAAGTACTGGAAACAAATGGCGCTCCAGGAGAAAGATGTT
AACACCCACTTTCCATTTTACCATTCTGAAAGATTTCTTAGATATCATGAATG
AACAAGCAAATATATTGGTTAAGAAACTTGAAAAACACATTAACCAAGAAGC
ATTTAACTGCTTTTTTTACATCACTCTTTGTGCCTTAGATATCATCTGTGAAAC
AGCTATGGGGAAGAATATTGGTGCTCAAAGTAATGATGATTCCGAGTATGTC
CGTGCAGTTTATAGAATGAGTGAGATGATATTTCGAAGAATAAAGATGCCCT
GGCTTTGGCTTGATCTCTGGTACCTTATGTTTAAAGAAGGATGGGAACACAA
AAAGAGCCTTAAGATCCTACATACTTTTACCAACAGTGTCATCGCGGAACGG
GCCAATGAAATGAACGCCAATGAAGACTGTAGAGGTGATGGCAGGGGCTCT
GCCCCCTCCAAAAATAAACGCAGGGCCTTTCTTGACTTGCTTTTAAGTGTGA
CTGATGACGAAGGGAACAGGCTAAGTCATGAAGATATTCGAGAAGAAGTTG
ACACCTTCATGTTTGAGGGGCACGATACAACTGCAGCTGCAATAAACTGGT
CCTTATACCTGTTGGGTTCTAACCCAGAAGTCCAGAAAAAAGTGGATCATGA
ATTGGATGACGTGTTTGGGAAGTCTGACCGTCCCGCTACAGTAGAAGACCT
GAAGAAACTTCGGTATCTGGAATGTGTTATTAAGGAGACCCTTCGCCTTTTT
CCTTCTGTTCCTTTATTTGCCCGTAGTGTTAGTGAAGATTGTGAAGTGGCAG
GTTACAGAGTTCTAAAAGGCACTGAAGCCGTCATCATTCCCTATGCATTGCA
CAGAGATCCGAGATACTTCCCCAACCCCGAGGAGTTCCAGCCTGAGCGGTT
CTTCCCCGAGAATGCACAAGGGCGCCATCCATATGCCTACGTGCCCTTCTC
TGCTGGCCCCAGGAACTGTATAGGTCAAAAGTTTGCTGTGATGGAAGAAAA
GACCATTCTTTCGTGCATCCTGAGGCACTTTTGGATAGAATCCAACCAGAAA
AGAGAAGAGCTTGGTCTAGAAGGACAGTTGATTCTTCGTCCAAGTAATGGC
ATCTGGATCAAGTTGAAGAGGAGAAATGCAGATGAACGCCATCATCATCATC
ATCATTAAGAATTCGATAAAAGAACCTATAATCCCTTCGCACACCGCGTCAC
ACCGCGCTATATGCTGCTCATTAGGAATTACGGCTCCTTTTTTGTGGATACA
ATCTCTTGTATACGATATACTTATTGTTAATTTCATTGACCTTTACGCAATCCT
GCGTAAATGCTGGTATAGGGTGTACTTCGGATTTCCGAGCCTATATTGGTTT
TGAAAGGACCTTTAAGTCCCTACTATACTACATTGTACTAGCGTAGGCCACG
TAGGCCCGTAAGATATTATAACTATTTTATTATATTTTATTCACCCCCCACATT
AATCCCAGTTAAAGCTTTATAACTATAAGTAAGCCGTGCCGAAACGTTAATC
GGTCGCTAGTTGCGTAACAACTGTTAGTTTAATTTTCCAAAATTTATTTTTCA
CAATTTTTAGTTAAGATTTTAGCTTGCCTTAAGCAGTCTTTATATCTTCTGTAT
ATTATTTTAAAGTTTATAGGAGCAAAGTTCGCTTTACTCGCAATAGCTATTTT
ATTTATTTTAGGAATATTATCACCTCGTAATTATTTAATTATAACATTAGCTTTA
TCTATTTATACCCGGGATTGGATCCACCGGTCGCCACCATGGGAGACTCCC
ACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAAGAAGTATCT
CTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTAA
CCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAA
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AATTCAGACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATG
AAGAAAACGGGGAGGAACATCATCGTGTTCTACGGCTCCCAGACGGGGAC
TGCAGAGGAGTTTGCCAACCGCCTGTCCAAGGACGCCCACCGCTACGGGA
TGCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGACCTGAGC
AGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCCACCTAC
GGTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCA
GGAGACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGG
GAACAAGACCTACGAGCACTTCAATGCCATGGGCAAGTACGTGGACAAGCG
GCTGGAGCAGCTCGGCGCCCAGCGCATCTTTGAGCTGGGGTTGGGCGACG
ACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAGCAGTTCTGG
CCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGGAGTCCAG
CATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGT
GTACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCC
CCTTTGATGCCAAGAATCCGTTCCTGGCTGCAGTCACCACCAACCGGAAGC
TGAACCAGGGAACCGAGCGCCACCTCATGCACCTGGAATTGGACATCTCG
GACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCTGTGTACCCAGCC
AACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGCCGACCTG
GACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAGCAC
CCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGAC
ATCACCAACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGCAGTACGC
CTCGGAGCCCTCGGAGCAGGAGCTGCTGCGCAAGATGGCCTCCTCCTCCG
GCGAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTGGAGGCCCGGAGGCA
CATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCCATCGACC
ACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATCGCCT
CATCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGG
AGTACGAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGG
CTGCGGGCCAAGGAGCCTGCCGGGGAGAACGGCGGCCGTGCGCTGGTGC
CCATGTTCGTGCGCAAGTCCCAGTTCCGCCTGCCCTTCAAGGCCACCACGC
CTGTCATCATGGTGGGCCCCGGCACCGGGGTGGCACCCTTCATAGGCTTC
ATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGGGGAGA
CGCTGCTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGG
GAGGAGCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCAGCTCAACGT
GGCCTTCTCCCGGGAGCAGTCCCACAAGGTCTACGTCCAGCACCTGCTAAA
GCAAGACCGAGAGCACCTGTGGAAGTTGATCGAAGGCGGTGCCCACATCT
ACGTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCAGAACACCTTC
TACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGCGGTGG
ACTACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGA
GCTAGGTCGAC 
 
 
Figure 28. Sequence information of 4V2-RhPV-IRES-OR in pFastbac.  
Restriction sites for cloning purpose are shown in Bold. The missense mutation 
was labeled in red. A should be replaced by G for correct 4V2 protein sequence. 
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GAATTCATGGCGGGGCTCTGGCTGGGGCTCGTGTGGCAGAAGCTGCTGCT
GTGGGGCGCGGCGAGTGCCCTTTCCCTGGCCGGCGCCAGTCTGGTCCTGA
GCCTGCTGCAGAGGGTGGCGAGCTACGCGCGGAAATGGCAGCAGATGCG
GCCCATCCCCACGGTGGCCCGCGCCTACCCACTGGTGGGCCACGCGCTGC
TGATGAAGCCGGACGGGCGAGAATTTTTTCAGCAGATCATTGAGTACACAG
AGGAATACCGCCACATGCCGCTGCTGAAGCTCTGGGTCGGGCCAGTGCCC
ATGGTGGCCCTTTATAATGCAGAAAATGTGGAGGTAATTTTAACTAGTTCAA
AGCAAATTGACAAATCCTCTATGTACAAGTTTTTAGAACCATGGCTTGGCCT
AGGACTTCTTACAAGTACTGGAAACAAATGGCGCTCCAGGAGAAAGATGTT
AACACCCACTTTCCATTTTACCATTCTGGAAGATTTCTTAGATATCATGAATG
AACAAGCAAATATATTGGTTAAGAAACTTGAAAAACACATTAACCAAGAAGC
ATTTAACTGCTTTTTTTACATCACTCTTTGTGCCTTAGATATCATCTGTGAAAC
AGCTATGGGGAAGAATATTGGTGCTCAAAGTAATGATGATTCCGAGTATGTC
CGTGCAGTTTATAGAATGAGTGAGATGATATTTCGAAGAATAAAGATGCCCT
GGCTTTGGCTTGATCTCTGGTACCTTATGTTTAAAGAAGGATGGGAACACAA
AAAGAGCCTTAAGATCCTACATACTTTTACCAACAGTGTCATCGCGGAACGG
GCCAATGAAATGAACGCCAATGAAGACTGTAGAGGTGATGGCAGGGGCTCT
GCCCCCTCCAAAAATAAACGCAGGGCCTTTCTTGACTTGCTTTTAAGTGTGA
CTGATGACGAAGGGAACAGGCTAAGTCATGAAGATATTCGAGAAGAAGTTG
ACACCTTCATGTTTGAGGGGCACGATACAACTGCAGCTGCAATAAACTGGT
CCTTATACCTGTTGGGTTCTAACCCAGAAGTCCAGAAAAAAGTGGATCATGA
ATTGGATGACGTGTTTGGGAAGTCTGACCGTCCCGCTACAGTAGAAGACCT
GAAGAAACTTCGGTATCTGGAATGTGTTATTAAGGAGACCCTTCGCCTTTTT
CCTTCTGTTCCTTTATTTGCCCGTAGTGTTAGTGAAGATTGTGAAGTGGCAG
GTTACAGAGTTCTAAAAGGCACTGAAGCCGTCATCATTCCCTATGCATTGCA
CAGAGATCCGAGATACTTCCCCAACCCCGAGGAGTTCCAGCCTGAGCGGTT
CTTCCCCGAGAATGCACAAGGGCGCCATCCATATGCCTACGTGCCCTTCTC
TGCTGGCCCCAGGAACTGTATAGGTCAAAAGTTTGCTGTGATGGAAGAAAA
GACCATTCTTTCGTGCATCCTGAGGCACTTTTGGATAGAATCCAACCAGAAA
AGAGAAGAGCTTGGTCTAGAAGGACAGTTGATTCTTCGTCCAAGTAATGGC
ATCTGGATCAAGTTGAAGAGGAGAAATGCAGATGAACGCCATCATCATCATC
ATCATTAAGCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATAAATATG
GCTGACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGA
AGAAGTATCTCTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTG
GGTCTCCTAACCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCG
AGTTCACCAAAATTCAGACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGT
GGAAAAGATGAAGAAAACGGGGAGGAACATCATCGTGTTCTACGGCTCCCA
GACGGGGACTGCAGAGGAGTTTGCCAACCGCCTGTCCAAGGACGCCCACC
GCTACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCC
GACCTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATG
GCCACCTACGGTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGA
CTGGCTGCAGGAGACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTT
TGGTCTTGGGAACAAGACCTACGAGCACTTCAATGCCATGGGCAAGTACGT
GGACAAGCGGCTGGAGCAGCTCGGCGCCCAGCGCATCTTTGAGCTGGGGT
TGGGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAG
CAGTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGA
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GGAGTCCAGCATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGC
GGCCAAGGTGTACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACC
AGAAGCCCCCCTTTGATGCCAAGAATCCGTTCCTGGCTGCAGTCACCACCA
ACCGGAAGCTGAACCAGGGAACCGAGCGCCACCTCATGCACCTGGAATTG
GACATCTCGGACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCTGTG
TACCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGT
GCCGACCTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAAC
AAGAAGCACCCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTAC
TACCTGGACATCACCAACCCGCCGCGTACCAACGTGCTGTACGAGCTGGC
GCAGTACGCCTCGGAGCCCTCGGAGCAGGAGCTGCTGCGCAAGATGGCCT
CCTCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTGGAGGC
CCGGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCC
CCATCGACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTAC
TCCATCGCCTCATCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCG
GTGGTTGTGGAGTACGAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGC
CACCAACTGGCTGCGGGCCAAGGAGCCTGCCGGGGAGAACGGCGGCCGT
GCGCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTCCGCCTGCCCTTCAAG
GCCACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGGTGGCACCCTT
CATAGGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGG
TGGGGGAGACGCTGCTGTACTACGGCTGCCGCCGCTCGGATGAGGACTAC
CTGTACCGGGAGGAGCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCA
GCTCAACGTGGCCTTCTCCCGGGAGCAGTCCCACAAGGTCTACGTCCAGC
ACCTGCTAAAGCAAGACCGAGAGCACCTGTGGAAGTTGATCGAAGGCGGT
GCCCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCA
GAACACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGC
AGGCGGTGGACTACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTG
GACGTGTGGAGCTAGAAGCTT 
 
Figure 29. Sequence information of 4V2-lg10-OR in pFastbac.  
Restriction sites for cloning purpose are shown in Bold. 
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GCGCGCATGGAACCTTCTTGGCTGCAGGAGCTGATGGCACACCCGTTCTTA
CTGCTGATCCTGTTATGTATGAGCCTGCTGTTATTCCAGGTCATTCGTTTATA
TCAGCGCCGTCGCTGGATGATTCGTGCGCTGCATTTATTCCCAGCCCCACC
GGCGCACTGGTTCTACGGCCATAAGGAATTCTACCCGGTGAAGGAGTTTGA
GGTCTATCACAAACTGATGGAGAAATACCCATGTGCGGTTCCGTTATGGGT
CGGTCCATTCACGATGTTCTTCAGCGTTCACGACCCAGATTACGCCAAAATT
CTGTTAAAGCGTCAGGACCCGAAATCTGCGGTGTCTCACAAGATTCTGGAA
AGCTGGGTTGGCCGTGGCCTGGTCACCCTGGACGGTTCTAAATGGAAAAAA
CATCGCCAAATTGTGAAGCCGGGCTTCAACATCAGCATTCTGAAAATCTTCA
TCACCATGATGAGCGAGAGCGTCCGCATGATGCTGAACAAGTGGGAGGAG
CATATTGCGCAGAACAGCCGCCTGGAGCTGTTCCAACACGTCAGCCTGATG
ACGTTAGATAGCATTATGAAATGCGCCTTTAGCCACCAGGGCAGCATCCAA
CTGGACAGCACCTTAGACAGCTACTTAAAGGCCGTGTTTAATCTGAGCAAG
ATTAGCAACCAACGTATGAACAACTTCCTGCACCACAACGACTTAGTGTTCA
AGTTCTCTAGCCAAGGCCAGATTTTTAGCAAGTTTAACCAGGAACTGCATCA
ATTCACCGAAAAGGTCATCCAAGATCGCAAGGAAAGCCTGAAGGACAAGCT
GAAACAGGACACGACGCAAAAGCGCCGCTGGGATTTCCTGGACATTCTGCT
GTCTGCCAAGAGCGAAAACACGAAGGATTTCTCTGAGGCAGATCTCCAGGC
CGAAGTGAAAACCTTCATGTTTGCCGGTCATGATACCACGTCTAGCGCAATT
TCTTGGATCCTGTATTGTCTGGCGAAATACCCGGAACACCAACAGCGTTGC
CGTGATGAAATTCGCGAGTTACTGGGTGACGGCAGCTCTATTACGTGGGAG
CACCTGTCTCAGATGCCATACACGACCATGTGTATTAAGGAATGCCTGCGC
CTGTATGCGCCGGTGGTCAACATCAGCCGCCTGCTGGACAAACCGATCACC
TTTCCAGACGGTCGCAGCCTGCCAGCGGGCATCACCGTCTTTATCAACATT
TGGGCACTGCATCATAACCCATACTTTTGGGAGGACCCGCAAGTGTTTAAC
CCGCTGCGCTTCAGCCGTGAAAATAGCGAGAAGATCCACCCGTATGCGTTC
ATCCCATTTAGCGCAGGTTTACGCAACTGCATTGGCCAGCACTTTGCGATCA
TTGAATGCAAAGTTGCAGTGGCGCTGACCCTGCTGCGTTTCAAGTTAGCGC
CAGATCATAGCCGTCCACCGCAGCCGGTTCGTCAAGTTGTGTTAAAGAGCA
AGAACGGTATCCACGTGTTTGCGAAAAAGGTCTGCCATCACCACCATCATC
ATTAACAATTCGATAAAAGAACCTATAATCCCTTCGCACACCGCGTCACACC
GCGCTATATGCTGCTCATTAGGAATTACGGCTCCTTTTTTGTGGATACAATC
TCTTGTATACGATATACTTATTGTTAATTTCATTGACCTTTACGCAATCCTGC
GTAAATGCTGGTATAGGGTGTACTTCGGATTTCCGAGCCTATATTGGTTTTG
AAAGGACCTTTAAGTCCCTACTATACTACATTGTACTAGCGTAGGCCACGTA
GGCCCGTAAGATATTATAACTATTTTATTATATTTTATTCACCCCCCACATTAA
TCCCAGTTAAAGCTTTATAACTATAAGTAAGCCGTGCCGAAACGTTAATCGG
TCGCTAGTTGCGTAACAACTGTTAGTTTAATTTTCCAAAATTTATTTTTCACAA
TTTTTAGTTAAGATTTTAGCTTGCCTTAAGCAGTCTTTATATCTTCTGTATATT
ATTTTAAAGTTTATAGGAGCAAAGTTCGCTTTACTCGCAATAGCTATTTTATTT
ATTTTAGGAATATTATCACCTCGTAATTATTTAATTATAACATTAGCTTTATCT
ATTTATACCCGGGATTGGATCCACCGGTCGCCACCATGGGAGACTCCCACG
TGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAAGAAGTATCTCTTT
TCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGTCTCCTAACCTA
CTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGTTCACCAAAATT
CAGACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGAAAAGATGAAG
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AAAACGGGGAGGAACATCATCGTGTTCTACGGCTCCCAGACGGGGACTGC
AGAGGAGTTTGCCAACCGCCTGTCCAAGGACGCCCACCGCTACGGGATGC
GAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGACCTGAGCAGC
CTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCCACCTACGGT
GAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTGGCTGCAGGA
GACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTGGTCTTGGGAA
CAAGACCTACGAGCACTTCAATGCCATGGGCAAGTACGTGGACAAGCGGCT
GGAGCAGCTCGGCGCCCAGCGCATCTTTGAGCTGGGGTTGGGCGACGAC
GATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAGCAGTTCTGGCC
GGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGGAGTCCAGCA
TTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGGCCAAGGTGT
ACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAGAAGCCCCCC
TTTGATGCCAAGAATCCGTTCCTGGCTGCAGTCACCACCAACCGGAAGCTG
AACCAGGGAACCGAGCGCCACCTCATGCACCTGGAATTGGACATCTCGGA
CTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCTGTGTACCCAGCCAA
CGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGCCGACCTGGA
CGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAAGAAGCACCC
ATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTACCTGGACAT
CACCAACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGCAGTACGCCT
CGGAGCCCTCGGAGCAGGAGCTGCTGCGCAAGATGGCCTCCTCCTCCGGC
GAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTGGAGGCCCGGAGGCACA
TCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCCATCGACCAC
CTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTCCATCGCCTCA
TCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGTGGTTGTGGAG
TACGAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGCCACCAACTGGCT
GCGGGCCAAGGAGCCTGCCGGGGAGAACGGCGGCCGTGCGCTGGTGCCC
ATGTTCGTGCGCAAGTCCCAGTTCCGCCTGCCCTTCAAGGCCACCACGCCT
GTCATCATGGTGGGCCCCGGCACCGGGGTGGCACCCTTCATAGGCTTCAT
CCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTGGGGGAGACG
CTGCTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCTGTACCGGGA
GGAGCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCAGCTCAACGTGG
CCTTCTCCCGGGAGCAGTCCCACAAGGTCTACGTCCAGCACCTGCTAAAGC
AAGACCGAGAGCACCTGTGGAAGTTGATCGAAGGCGGTGCCCACATCTAC
GTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCAGAACACCTTCTA
CGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAGGCGGTGGAC
TACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGACGTGTGGAGC
TAGGTCGAC 
 
Figure 30. Sequence information of 4Z1-RhPV-IRES-OR in pFastbac.  
Restriction sites for cloning purpose are shown in Bold. 
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GCGCGCATGGAACCTTCTTGGCTGCAGGAGCTGATGGCACACCCGTTCTTA
CTGCTGATCCTGTTATGTATGAGCCTGCTGTTATTCCAGGTCATTCGTTTATA
TCAGCGCCGTCGCTGGATGATTCGTGCGCTGCATTTATTCCCAGCCCCACC
GGCGCACTGGTTCTACGGCCATAAGGAATTCTACCCGGTGAAGGAGTTTGA
GGTCTATCACAAACTGATGGAGAAATACCCATGTGCGGTTCCGTTATGGGT
CGGTCCATTCACGATGTTCTTCAGCGTTCACGACCCAGATTACGCCAAAATT
CTGTTAAAGCGTCAGGACCCGAAATCTGCGGTGTCTCACAAGATTCTGGAA
AGCTGGGTTGGCCGTGGCCTGGTCACCCTGGACGGTTCTAAATGGAAAAAA
CATCGCCAAATTGTGAAGCCGGGCTTCAACATCAGCATTCTGAAAATCTTCA
TCACCATGATGAGCGAGAGCGTCCGCATGATGCTGAACAAGTGGGAGGAG
CATATTGCGCAGAACAGCCGCCTGGAGCTGTTCCAACACGTCAGCCTGATG
ACGTTAGATAGCATTATGAAATGCGCCTTTAGCCACCAGGGCAGCATCCAA
CTGGACAGCACCTTAGACAGCTACTTAAAGGCCGTGTTTAATCTGAGCAAG
ATTAGCAACCAACGTATGAACAACTTCCTGCACCACAACGACTTAGTGTTCA
AGTTCTCTAGCCAAGGCCAGATTTTTAGCAAGTTTAACCAGGAACTGCATCA
ATTCACCGAAAAGGTCATCCAAGATCGCAAGGAAAGCCTGAAGGACAAGCT
GAAACAGGACACGACGCAAAAGCGCCGCTGGGATTTCCTGGACATTCTGCT
GTCTGCCAAGAGCGAAAACACGAAGGATTTCTCTGAGGCAGATCTCCAGGC
CGAAGTGAAAACCTTCATGTTTGCCGGTCATGATACCACGTCTAGCGCAATT
TCTTGGATCCTGTATTGTCTGGCGAAATACCCGGAACACCAACAGCGTTGC
CGTGATGAAATTCGCGAGTTACTGGGTGACGGCAGCTCTATTACGTGGGAG
CACCTGTCTCAGATGCCATACACGACCATGTGTATTAAGGAATGCCTGCGC
CTGTATGCGCCGGTGGTCAACATCAGCCGCCTGCTGGACAAACCGATCACC
TTTCCAGACGGTCGCAGCCTGCCAGCGGGCATCACCGTCTTTATCAACATT
TGGGCACTGCATCATAACCCATACTTTTGGGAGGACCCGCAAGTGTTTAAC
CCGCTGCGCTTCAGCCGTGAAAATAGCGAGAAGATCCACCCGTATGCGTTC
ATCCCATTTAGCGCAGGTTTACGCAACTGCATTGGCCAGCACTTTGCGATCA
TTGAATGCAAAGTTGCAGTGGCGCTGACCCTGCTGCGTTTCAAGTTAGCGC
CAGATCATAGCCGTCCACCGCAGCCGGTTCGTCAAGTTGTGTTAAAGAGCA
AGAACGGTATCCACGTGTTTGCGAAAAAGGTCTGCCATCACCACCATCATC
ATTAAGCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATAAATATGGCT
GACTCCCACGTGGACACCAGCTCCACCGTGTCCGAGGCGGTGGCCGAAGA
AGTATCTCTTTTCAGCATGACGGACATGATTCTGTTTTCGCTCATCGTGGGT
CTCCTAACCTACTGGTTCCTCTTCAGAAAGAAAAAAGAAGAAGTCCCCGAGT
TCACCAAAATTCAGACATTGACCTCCTCTGTCAGAGAGAGCAGCTTTGTGGA
AAAGATGAAGAAAACGGGGAGGAACATCATCGTGTTCTACGGCTCCCAGAC
GGGGACTGCAGAGGAGTTTGCCAACCGCCTGTCCAAGGACGCCCACCGCT
ACGGGATGCGAGGCATGTCAGCGGACCCTGAGGAGTATGACCTGGCCGAC
CTGAGCAGCCTGCCAGAGATCGACAACGCCCTGGTGGTTTTCTGCATGGCC
ACCTACGGTGAGGGAGACCCCACCGACAATGCCCAGGACTTCTACGACTG
GCTGCAGGAGACAGACGTGGATCTCTCTGGGGTCAAGTTCGCGGTGTTTG
GTCTTGGGAACAAGACCTACGAGCACTTCAATGCCATGGGCAAGTACGTGG
ACAAGCGGCTGGAGCAGCTCGGCGCCCAGCGCATCTTTGAGCTGGGGTTG
GGCGACGACGATGGGAACTTGGAGGAGGACTTCATCACCTGGCGAGAGCA
GTTCTGGCCGGCCGTGTGTGAACACTTTGGGGTGGAAGCCACTGGCGAGG
AGTCCAGCATTCGCCAGTACGAGCTTGTGGTCCACACCGACATAGATGCGG
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CCAAGGTGTACATGGGGGAGATGGGCCGGCTGAAGAGCTACGAGAACCAG
AAGCCCCCCTTTGATGCCAAGAATCCGTTCCTGGCTGCAGTCACCACCAAC
CGGAAGCTGAACCAGGGAACCGAGCGCCACCTCATGCACCTGGAATTGGA
CATCTCGGACTCCAAAATCAGGTATGAATCTGGGGACCACGTGGCTGTGTA
CCCAGCCAACGACTCTGCTCTCGTCAACCAGCTGGGCAAAATCCTGGGTGC
CGACCTGGACGTCGTCATGTCCCTGAACAACCTGGATGAGGAGTCCAACAA
GAAGCACCCATTCCCGTGCCCTACGTCCTACCGCACGGCCCTCACCTACTA
CCTGGACATCACCAACCCGCCGCGTACCAACGTGCTGTACGAGCTGGCGC
AGTACGCCTCGGAGCCCTCGGAGCAGGAGCTGCTGCGCAAGATGGCCTCC
TCCTCCGGCGAGGGCAAGGAGCTGTACCTGAGCTGGGTGGTGGAGGCCC
GGAGGCACATCCTGGCCATCCTGCAGGACTGCCCGTCCCTGCGGCCCCCC
ATCGACCACCTGTGTGAGCTGCTGCCGCGCCTGCAGGCCCGCTACTACTC
CATCGCCTCATCCTCCAAGGTCCACCCCAACTCTGTGCACATCTGTGCGGT
GGTTGTGGAGTACGAGACCAAGGCCGGCCGCATCAACAAGGGCGTGGCCA
CCAACTGGCTGCGGGCCAAGGAGCCTGCCGGGGAGAACGGCGGCCGTGC
GCTGGTGCCCATGTTCGTGCGCAAGTCCCAGTTCCGCCTGCCCTTCAAGGC
CACCACGCCTGTCATCATGGTGGGCCCCGGCACCGGGGTGGCACCCTTCA
TAGGCTTCATCCAGGAGCGGGCCTGGCTGCGACAGCAGGGCAAGGAGGTG
GGGGAGACGCTGCTGTACTACGGCTGCCGCCGCTCGGATGAGGACTACCT
GTACCGGGAGGAGCTGGCGCAGTTCCACAGGGACGGTGCGCTCACCCAG
CTCAACGTGGCCTTCTCCCGGGAGCAGTCCCACAAGGTCTACGTCCAGCAC
CTGCTAAAGCAAGACCGAGAGCACCTGTGGAAGTTGATCGAAGGCGGTGC
CCACATCTACGTCTGTGGGGATGCACGGAACATGGCCAGGGATGTGCAGA
ACACCTTCTACGACATCGTGGCTGAGCTCGGGGCCATGGAGCACGCGCAG
GCGGTGGACTACATCAAGAAACTGATGACCAAGGGCCGCTACTCCCTGGAC
GTGTGGAGCTAGAAGCTT 
 
 
Figure 31. Sequence information of 4Z1-lg10-OR in pFastbac.  
Restriction sites for cloning purpose are shown in Bold. 
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P450 4V2 (nM) 
 
P450 4Z1 (nM) 
 
mono-cistronic system 
 
24 
 
8 
dual promoter system 3.6 1.8 
bi-cistronic system (lg10 IRES) 6 4.8 
bi-cistronic system (RhPV IRES) 5.4 6 
 
Table 9. Expression levels of P450 4V2 and 4Z1 in insect cells. 
 
 
Expression of human P450 2U1 in an E. coli expression system 
Expression of human P450 2U1 has been established in insect cells 
without pursuit of protein purification (39). Expression (180 nM) has also been 
achieved in an E. coli expression system (37) with codon-optimized for several 
amino acids at the N-terminal. To explore the possibility of obtaining active 
human P450 2U1 in E. coli expression systems with a higher yield, an expression 
vector was constructed with codon-optimized for the entire N-terminal modified 
coding sequence (38). The best expression level (420 nM) was obtained with co-
expression of GroES/EL and a N-terminal modification of MAKKTSSKGKLP in 
TOP10 cells (38).  
 
Expression of human 46A1 in an E. coli expression system 
The expression of the native sequence as described in (176) was 
unsuccessful until codon-optimization was performed with the entire N-terminal 
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modified coding sequence (107). The best yield (600 nM) was obtained with co-
expression of GroES/EL in DH5α cells (107). 
 
Discussion 
To obtain P450 enzymes for future functional studies, heterologous 
expression systems were established for human P450 46A1 and 2U1 (E. coli 
expression systems) as well as for human P450 4V2 and 4Z1 (baculovirus 
expression systems). Co-expression of NADPH-P450 reductase and P450 4V2/ 
4Z1 was also achieved with bi-cistronic systems in insect cells. 
The difficulties in expressing membrane-bound proteins are well 
recognized. Correct incorporation of heme is another obstacle in P450 
expression. Since obtaining active P450 enzymes in high yields is usually the 
prerequisite for functional studies, many contributing factors have been 
summarized in a few review articles (93, 105). Although most P450 enzymes can 
be expressed in satisfactory yields with either an E. coli expression system or a 
baculovirus expression system, heterologous expression could still be the 
bottleneck for many research projects.  
Codon-optimization helps protein translation and could increase 
expression levels significantly in E. coli expression systems. Although an 
increase in protein expression is not guaranteed (i.e., human P450 4Z1), codon-
optimization is still recommended as a common practice for the heterologous 
expression of all P450 enzymes in E. coli expression systems. In-house PCR 
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based gene synthesis is no longer a common practice, as out-sourcing to 
contract research companies (e.g., Genewiz, Genscript, etc.) is more cost-
effective. Although algorithms offered by different vendors (e.g., Genscript, 
Genewiz, IDT) could differ in their capability to increase protein expression 
levels, no case has been reported that one algorithm is significantly better than 
others. Since codon-optimization aids in protein translation, it is plausible to 
perform codon-optimization for the entire coding sequence. The more codons are 
optimized, the higher the expression level could be achieved. One good example 
is the expression of human P450 2U1: N-terminal modified native coding 
sequence gave an expression level of 50 nM; an optimized N-terminal but not the 
entire coding sequence gave an expression level of 180 nM; optimizing the entire 
coding sequence gave an expression level of 420 nM (37).  
N-Terminal modifications can be designed according to successful 
examples reported in the literature (64, 93-95, 97, 98, 100, 103, 109-112). 
Although high expression levels have been obtained with many different N-
terminal modifications, it is time consuming to test all of these modifications with 
every new P450 enzyme. Therefore, it is recommended to perform expression 
trials with two commonly seen modifications, MALLLAVFL and MAKKTSS, plus 
3-4 other modifications in parallel.  
Co-expression of different chaperones can be tested to increase 
expression level, but rarely did the use of a chaperone other than GroES/EL 
gives higher expression level.  
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Failure in getting any P450 spectrum after testing all of the N-terminal 
modifications with GroES/EL co-expression could suggest switching from E. coli 
expression systems to other expression systems (e.g., yeast or baculovirus 
expression systems). 
In addition to those contributing factors described above, personal 
experience suggests that there are other less recognized factors that also affect 
yields of P450 expression. 1) Aeration: aeration is commonly taken into 
consideration in large-scale fermentations and is plausible that it also affect 
yields in small-scale protein expressions commonly used in research 
laboratories. Aeration was first speculated to effect protein expression levels with 
the failure to express human P450 2S1. Although the expression method has 
been established and published (36), difficulties have been encountered in 
obtaining active P450 2S1 with the same method (data not shown). Later trials 
found that the expression in 50 ml medium (in 250 ml shaking flasks) always 
gave much more active enzyme than the expression in 500 ml medium (in 2.8 l 
shaking flasks) (the same result has been observed by Dr. Pavel Souček, 
personal communication). Another example is the expression of human P450 
4F11 (data not shown). The expression at a low shaking speed (120 rpm) gave 
much more yield then the expression at 200 rpm. 2) Expression temperature: low 
expression temperature decreases the rate of transcription/translation but could 
also give more time for protein folding and heme incorporation. The optimal 
expression temperature has to be determined by trial and error. 3) Bacterial 
strain: DH5α is the most commonly used one for P450 expression. Many early 
  
106 
publications reported the use of DH5α F’IQ (36), but no significant difference in 
expression levels was found between these two strains. 4) Other unidentified 
factor(s): although human P450 2S1 was successfully expressed with 50 ml 
bacterial culture, it is still not clear why the expression in 500 ml culture medium 
cannot be reproduced. The failure in reproducing protein expression with the 
same procedure as described in Dr. Zhongliu Wu’s notebook (same plasmid, 
expression temperature, medium, shaking speed, and incubator) may suggest 
other factors that have not been recognized before. The failure to express human 
P450 46A1 with the same protocol described in (176) also indicates the 
involvement of that some previously un-recognized factors in successful 
expression of P450 enzymes.  
Unfortunately, not every P450 enzyme can be expressed with an E. coli 
expression system with high yield. Baculovirus expression systems can be used 
as alternatives since it also has the potential of generating functional P450 
enzymes with satisfactory yields. Although insect cell expression systems are 
becoming more and more user-friendly (i.e., switching from spinner flasks to 
shaker flasks, the introduction of automated cell counters and serum-free media), 
it is still not a common practice in many laboratories due to its high cost and 
technical requirements. Therefore, it is highly recommended to consult with an 
experienced expert before setting up a baculovirus expression system from 
scratch.  
The detection of P450 4Z1 by immunoblotting in the membrane fraction of 
4Z1-expressed E. coli cells indicates that the polypeptide was successfully 
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translated. However, the absence of a P450 spectrum indicates 1) the translated 
polypeptide never yielded any catalytic activity or 2) the catalytic activity was lost 
quickly during membrane isolation. Given the fact that P450 spectra can be 
observed in the membrane fraction collected from 4Z1-expressed insect cells 
(Figure 26), it is very likely that active P450 4Z1 was never produced in the E. 
coli, and E. coli is probably not capable of expressing active P450 4Z1 due to 
some inherent yet unknown difficulties. Thus, further attempt to express human 
P450 4Z1 in E. coli cells (e.g., other strains, other N-terminal modifications, etc.) 
was not pursued.  
In summary, heterologous expression systems for human P450 2U1, 4V2, 
4Z1, and 46A1 were established for future functional assays, and contributing 
factors are summarized to facilitate future protein expression trials. 
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CHAPTER V 
 
SUMMARY AND CONCLUSIONS 
 
Functional annotation of orphan human P450 2S1, 2W1, and 4X1 by 
metabolomic approach is described in Chapter II and III. The heterologous 
expressions of human P450 2U1, 4V2, 4Z1, and 46A1 are described in chapter 
IV. Functional studies with P450 2S1 indicate its capability to accept electrons 
from NADPH-P450 reductase (177), although no physiological significance has 
been identified so far. Functional studies with human P450 2W1 revealed a 
series of lysophospholipids as substrates. No endogenous substrate was 
identified for human P450 2S1 or 4X1. The heterologous expression of human 
P450 2U1 led to the identification of endogenous N-arachidonoylserotonin as a 
substrate (38). The heterologous expression of P450 46A1 led to the 
identification of 7-dehydrocholesterol and desmosterol as substrates (107). 
Heterologous expressions for P450 4V2 and 4Z1 in insect cells have been 
achieved in low yields, and isolated membrane fractions could be used for future 
functional studies. 
The past few years have seen tremendous advances in MS-based 
metabolomic studies. Advanced instruments with better sensitivity are constantly 
being introduced to the market, and software systems with better data 
analysis/visualization capabilities are being developed for public use. As a result, 
metabolomic studies have been introduced to many fields: the agricultural 
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industry uses untargeted metabolomics to study flavors (178, 179); clinical labs 
use untargeted metabolomics to identify biomarkers for diagnostic purposes 
(180); pharmaceutical companies use targeted metabolomics to study drug 
metabolism (181).  
Despite the exploding number of metabolomic studies found in literature, 
obtaining comprehensive metabolome coverage is still the bottleneck of many 
research projects. Breakthrough in this field could greatly benefit modern 
biomedical studies.  
Several MS based methodologies can be used to maximize metabolome 
coverage: 1) collect data with different instruments (i.e., GC-MS, LC-MS, CE-
MS); 2) use multiple ionization methods (i.e., ESI, APCI); 3) use different 
derivatization methods to increase sensitivity towards certain classes of 
compounds (e.g., dansylation (89)); 4) fractionate metabolome before data 
collection (i.e., by different extraction methods (182, 183)); 5) use different 
chromatography methods (e.g., longer gradient, reversed-phase, HILIC (88)).  
A pragmatic approach for metabolomic studies, especially for those 
involved with large amounts of samples, balances both sample throughput and 
comprehensive metabolome coverage. One can always increase throughput 
(e.g., run a faster LC gradient), albeit at the expense of sensitivity and 
metabolome coverage. Thus, having some knowledge or assumption about the 
most relevant classes of compounds can tremendously help study designs by 
allocating recourses in a cost-effective manner. 
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Most substrates and products of P450 enzymes are non-polar small 
molecules that can be detected by LC-MS with either ESI or APCI ionization 
mode and can be well resolved by a reversed-phase column. A dansylation 
method has also been developed to increase the sensitivity towards unactivated 
alcohols (89), a class of commonly seen P450 products. Thus, our proposed 
untargeted metabolomic approaches have identified many substrates for orphan 
human P450 enzymes (13, 38).  
Two different data analysis approaches were proposed to identify 
reactions catalyzed by P450 enzymes: 1) identify difference(s) with and without 
functional enzyme; 2) search for doublet patterns for monooxygenation reactions. 
LC-MS data deconvolution is the foundation of both approaches. The major 
disadvantage of the previously reported software system for doublet search, 
DoGEX, is that it searches for doublets without data deconvolution, which leads 
to the identification of large amounts of false-positives (i.e., from peak shoulders) 
that have to be excluded by manual inspections (Table 3).  
The doublet search approach was originally proposed to search for a 
signal intensity ratio M/M+2 close to 0.95 (14, 85, 184) or from 0.67 to 1.5 (13) in 
data collected on a Thermo LTQ instrument, which is based on the assumption 
that little 16O incorporated monooxygenated product can be found in the tissue 
extract (Figure 32). Although the assumption has been challenged and searches 
with a wider intensity ratio window is desired, the use of a narrow window 
continued, mainly to avoid the over-whelming amount of false-positives that could 
be generated with a wider intensity ratio window. This situation can be 
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tremendously improved with HRMS (Figure 32): with a Thermo LTQ Orbitrap 
instrument and a resolving power of 60,000, a much narrower mass difference 
window (2.001-2.006) can be used to search for doublet patterns and 
consequently the amount of false-positives can be magnificently decreased. As a 
result, even if a much wider intensity ratio window (0.01-1.5) is used, the amount 
of doublet candidates identified is still acceptable (Table 10). Therefore, the 
chance of identifying a monooxygenation reaction may increase and it is 
recommended to collect data with the Thermo LTQ Orbitrap instrument for 
incubations with 16O2/18O2 gas. 
 
 
 
 
Figure 32. Doublet searches enhanced by HRMS 
If there is little monooxygenated product present in the tissue extracts, an 
intensity ratio about 1:1 can be expected (A); However, if there is already some 
monooxygenated product in the tissue extracts, the intensity ratio is not 
necessarily 1:1 (2:1 in this particular case). These doublets can be identified with 
the help of HRMS (Table 10). 
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  mass difference window 
intensity  
ratio window 
number of candidates 
identified 
LTQ (1.9, 2.2) (0.67, 1.5) ~ 200 
LTQ-Orbitrap  (2.001, 2.006) (0.01, 1.5) ~ 200 
 
 
Table 10. Doublet searches with LTQ and LTQ-Orbitrap instruments. 
With the help of HRMS provided by a LTQ Orbitrap instrument, similar amounts 
of doublet candidates can be identified with a much narrower mass difference 
window and a much wider intensity ratio window. 
 
 
Combined with LC-MS data deconvolution and HRMS, it is also possible 
to make software systems to search for reactions with the addition or loss of 
certain masses, in an targeted (mass defect (181)) or untargeted manner. 
Untargeted reaction searches would be designed to search for dealkylation 
reactions, where one can look for two peak features that: 1) with a mass 
difference of 14.016; 2) decrease of substrate intensity or increase of product 
intensity after enzymatic incubation; 3) the dealkylated product should be eluted 
earlier than the substrate due to decreased hydrophobicity (if a reversed-phase 
column is used). Unfortunately P450-catalyzed dealkylation reactions happen 
mostly with xenobiotics, and thus the system described above is not applicable in 
searches for endogenous substrates. 
The failure to identify the accumulation of P450 2W1-mediated 18:1 LPC 
oxidation products by XCMS is very likely due to 1) too vigorous a smoothing 
method was used 2) the minimal intensity threshold was set too high. Thus, it 
might be beneficial to revisit and adjust parameters in XCMS. Nevertheless, both 
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incubation with 16O2/18O2 gas and XCMS analysis are recommended for 
substrate searches to maximize the chance of identifying an enzymatic reaction. 
Even if an enzyme is functionally annotated with a catalytic activity, its 
physiological significance may still have not been fully revealed. The 
physiological relevance of the enzymatic activities may be unclear (i.e., fatty acid 
oxidations by many orphan human P450 enzymes (39, 40, 42), 
lysophospholipids oxidations by P450 2W1 (13), N-arachidonoylserotonin 
oxidation by P450 2U1 (38)). In addition, other enzymes may be present in the 
same tissue catalyzing the same reaction. Even for an enzyme whose 
physiological significance is believed to be fully characterized, new catalytic 
activities could still be identified afterwards.  For example, P450 46A1 was 
originally known as a cholesterol 24-hydroxylase; however 7-dehydrocholesterol 
and desmosterol have recently been identified as its substrates as well (107). 
Therefore, any identified catalytic activity does not exclude the possibility that 
there are other physiological significances yet to be discovered.  
The recommended procedure to express a new P450 enzyme of interest 
begins with codon-optimization of the entire coding sequence for E. coli 
expression systems. Expression trials with several N-terminal modifications are 
recommended, including MALLLAVFL and MAKKTSS. The best N-terminal 
modification can be selected in expression trials with cells cultured in 50 ml 
medium (in 250 ml flasks). The expression of the selected N-terminal can be 
further optimized by trials with and without GroES/EL co-expression, in both 50 
ml medium (in 250 ml flasks) and in 500 ml medium (in 2.8 l flasks). Failure in 
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obtaining any P450 spectrum at this stage could suggest switching from E. coli to 
other expression systems (e.g., yeast or baculovirus expression systems). If a 
solid P450 spectrum can be obtained in an E. coli expression system, further 
optimization could be performed (shaking speed, expression temperature, and E. 
coli strains) if needed.  
To summarize, I have investigated catalytic activities of orphan human 
P450 2S1, 2W1, and 4X1. Heterologous expression systems for human P450 
2U1, 4V2, 4Z1, and 46A1 have been established for functional studies. LC-MS 
based metabolomic studies identified a series of lysophospholipids as substrates 
of human P450 2W1. No endogenous substrate was identified for human P450 
2S1 or 4X1. A new software system has been established to search for isotopic 
patterns in LC-MS data with improved efficiencies.  
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